HPC8
MCID: PRS130
MIFTS: 37

Prostate Cancer, Hereditary, 8 (HPC8)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer, Hereditary, 8

MalaCards integrated aliases for Prostate Cancer, Hereditary, 8:

Name: Prostate Cancer, Hereditary, 8 58
Predisposing for Prostate Cancer 58 13
Predisposing for Prostate Cancer; Pcap 58
Prostate Cancer, Susceptibility to 58
Prostate Cancer 58
Hpc8 58
Pcap 58

Classifications:



External Ids:

OMIM 58 602759
MedGen 43 C1864472

Summaries for Prostate Cancer, Hereditary, 8

MalaCards based summary : Prostate Cancer, Hereditary, 8, also known as predisposing for prostate cancer, is related to prostate cancer and prostate cancer, hereditary, 6. An important gene associated with Prostate Cancer, Hereditary, 8 is PCAP (Predisposing For Prostate Cancer). Affiliated tissues include prostate, bone and lymph node.

Description from OMIM: 602759

Related Diseases for Prostate Cancer, Hereditary, 8

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 1 Prostate Cancer, Hereditary, 8
Prostate Cancer, Hereditary, 3 Prostate Cancer, Hereditary, 4
Prostate Cancer, Hereditary, 5 Prostate Cancer, Hereditary, 6
Prostate Cancer, Hereditary, 7 Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 10 Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 13 Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 14 Prostate Cancer, Hereditary, 15
Prostate Cancer, Hereditary, 2 Prostate Carcinoma in Situ

Diseases related to Prostate Cancer, Hereditary, 8 via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 585, show less)
# Related Disease Score Top Affiliating Genes
1 prostate cancer 13.1
2 prostate cancer, hereditary, 6 12.7
3 prostate cancer, hereditary, 1 12.7
4 prostate cancer, hereditary, 2 12.6
5 prostate cancer, hereditary, 13 12.6
6 prostate cancer, hereditary, 12 12.6
7 prostate cancer, hereditary, 4 12.6
8 prostate cancer, hereditary, 11 12.5
9 prostate cancer, hereditary, 7 12.4
10 prostate cancer, hereditary, 3 12.4
11 prostate cancer/brain cancer susceptibility 12.4
12 prostate cancer, hereditary, x-linked 1 12.4
13 prostate cancer, hereditary, 9 12.4
14 prostate cancer, hereditary, x-linked 2 12.2
15 prostate cancer, hereditary, 5 12.2
16 prostate cancer, hereditary, 10 12.2
17 prostate cancer, hereditary, 14 12.2
18 prostate cancer, hereditary, 15 12.2
19 prostate cancer, progression and metastasis of 12.1
20 prostate cancer aggressiveness quantitative trait locus on chromosome 19 12.1
21 prostate disease 11.5
22 radiation proctitis 11.4
23 cone-rod dystrophy and hearing loss 2 11.1
24 prostate sarcoma 11.1
25 brca1 hereditary breast and ovarian cancer syndrome 11.1
26 brca2 hereditary breast and ovarian cancer syndrome 11.1
27 diethylstilbestrol syndrome 11.1
28 pachyonychia congenita 3 10.9
29 prostatic hyperplasia, benign 10.9
30 colorectal adenoma 10.9
31 prostatic adenoma 10.8
32 patulous eustachian tube 10.8
33 hypoxia 10.7
34 impotence 10.6
35 insulin-like growth factor i 10.6
36 prostatitis 10.5
37 breast cancer 10.5
38 renal oncocytoma 10.5
39 chronic interstitial cystitis 10.5
40 leukemia 10.5
41 retinoblastoma 10.5
42 adenocarcinoma 10.5
43 bladder cancer 10.4
44 osteoporosis 10.4
45 body mass index quantitative trait locus 1 10.4
46 sexual disorder 10.4
47 hypogonadism 10.4
48 hypogonadotropism 10.4
49 prostatic hypertrophy 10.4
50 depression 10.4
51 disseminated intravascular coagulation 10.4
52 melanoma 10.3
53 bone disease 10.3
54 proctitis 10.3
55 osteonecrosis 10.3
56 rheumatoid arthritis 10.3
57 withdrawal disorder 10.3
58 osteonecrosis of the jaw 10.3
59 myopathy, myosin storage, autosomal recessive 10.3
60 anxiety 10.3
61 human immunodeficiency virus type 1 10.3
62 lymphoma 10.3
63 infant gynecomastia 10.3
64 gynecomastia 10.3
65 myeloma, multiple 10.3
66 blood group, junior system 10.3
67 neutropenia 10.3
68 adenoma 10.3
69 colorectal cancer 10.2
70 alopecia 10.2
71 diabetes mellitus 10.2
72 androgenic alopecia 10.2
73 sclerosing cholangitis, neonatal 10.2
74 nuchal bleb, familial 10.2
75 chronic fatigue syndrome 10.2
76 headache associated with sexual activity 10.2
77 bone resorption disease 10.2
78 herpes simplex 10.2
79 heparin-induced thrombocytopenia 10.2
80 renal cell carcinoma, nonpapillary 10.2
81 ovarian cancer 10.2
82 horns in sheep 10.2
83 cystitis 10.2
84 vaccinia 10.2
85 lynch syndrome 10.2
86 suppression of tumorigenicity 12 10.1
87 inguinal hernia 10.1
88 obstructive nephropathy 10.1
89 alopecia, androgenetic, 1 10.1
90 blood group, colton system 10.1
91 diabetes mellitus, noninsulin-dependent 10.1
92 pemphigus foliaceus 10.1
93 neuroendocrine carcinoma 10.1
94 carney complex, type 1 10.1
95 lung cancer 10.1
96 neutrophil actin dysfunction 10.1
97 caronte 10.1
98 meningioma, familial 10.1
99 bone mineral density quantitative trait locus 8 10.1
100 bone mineral density quantitative trait locus 15 10.1
101 fecal incontinence 10.1
102 osteomyelitis 10.1
103 osteomalacia 10.1
104 sarcoma 10.1
105 pituitary apoplexy 10.1
106 spinal meningioma 10.1
107 secretory meningioma 10.1
108 stomatitis 10.1
109 isolated optic neuritis 10.1
110 retinitis pigmentosa 10.0
111 aging 10.0
112 tropical calcific pancreatitis 10.0
113 gastric cancer 10.0
114 helix syndrome 10.0
115 neuroendocrine tumor 10.0
116 urethral stricture 10.0
117 rectum cancer 10.0
118 testicular cancer 10.0
119 mammary paget's disease 10.0
120 hyperglycemia 10.0
121 lymphocele 10.0
122 urinary tract obstruction 10.0
123 neuropathy 10.0
124 priapism 10.0
125 cytokine deficiency 10.0
126 blood group--wright antigen 10.0
127 retinitis pigmentosa 1 10.0
128 lymphoma, hodgkin, classic 10.0
129 xeroderma pigmentosum, variant type 10.0
130 human herpesvirus 8 10.0
131 nevus comedonicus 10.0
132 japanese encephalitis 10.0
133 conn's syndrome 10.0
134 hemolytic-uremic syndrome 10.0
135 squamous cell papilloma 10.0
136 papilloma 10.0
137 neurilemmoma 10.0
138 pituitary adenoma 10.0
139 ureteral obstruction 10.0
140 paraplegia 10.0
141 radiation cystitis 10.0
142 exophthalmos 10.0
143 polymyositis 10.0
144 xp22.3 microdeletion syndrome 10.0
145 rapidly involuting congenital hemangioma 10.0
146 neurofibromatosis, type ii 10.0
147 multiple sclerosis 10.0
148 triiodothyronine receptor auxiliary protein 10.0
149 disorganization, mouse, homolog of 10.0
150 androgen insensitivity syndrome 10.0
151 body mass index quantitative trait locus 11 10.0
152 arts syndrome 10.0
153 body mass index quantitative trait locus 8 10.0
154 body mass index quantitative trait locus 10 10.0
155 body mass index quantitative trait locus 7 10.0
156 intraocular pressure quantitative trait locus 10.0
157 body mass index quantitative trait locus 14 10.0
158 muscle hypertrophy 10.0
159 body mass index quantitative trait locus 18 10.0
160 body mass index quantitative trait locus 19 10.0
161 thrombocytopenia 10.0
162 hypophosphatemia 10.0
163 inflammatory bowel disease 10.0
164 small cell carcinoma 10.0
165 thrombotic thrombocytopenic purpura 10.0
166 squamous cell carcinoma 10.0
167 hyperinsulinism 10.0
168 lipid metabolism disorder 10.0
169 purpura 10.0
170 muscular atrophy 10.0
171 appendicitis 10.0
172 glioblastoma 10.0
173 syndrome of inappropriate antidiuretic hormone 10.0
174 alzheimer disease 9.9
175 leukemia, chronic lymphocytic 2 9.9
176 hepatocellular carcinoma 9.9
177 elastosis perforans serpiginosa 9.9
178 factor viii deficiency 9.9
179 hypertriglyceridemia, familial 9.9
180 leukemia, chronic lymphocytic 9.9
181 temporal arteritis 9.9
182 bloom syndrome 9.9
183 bornholm eye disease 9.9
184 hemophilia a 9.9
185 gonadoblastoma 9.9
186 gastrointestinal stromal tumor 9.9
187 li-fraumeni syndrome 2 9.9
188 myelodysplastic syndrome 9.9
189 hyperprolactinemia 9.9
190 arthritis 9.9
191 congestive heart failure 9.9
192 end stage renal failure 9.9
193 hepatitis 9.9
194 liver disease 9.9
195 lymphedema 9.9
196 dermatomyositis 9.9
197 lymphocytic leukemia 9.9
198 heart disease 9.9
199 diphtheria 9.9
200 pancytopenia 9.9
201 dementia 9.9
202 gout 9.9
203 hyperparathyroidism 9.9
204 premature ejaculation 9.9
205 optic nerve disease 9.9
206 rectosigmoid cancer 9.9
207 newcastle disease 9.9
208 peripheral nervous system disease 9.9
209 measles 9.9
210 myeloid leukemia 9.9
211 pemphigus 9.9
212 encephalitis 9.9
213 fasciitis 9.9
214 hemophilia 9.9
215 rere-related disorders 9.9
216 acquired hemophilia 9.9
217 glyceraldehyde-3-phosphate dehydrogenase deficiency 9.9
218 leukemia, b-cell, chronic 9.9
219 malakoplakia 9.9
220 oncogenic osteomalacia 9.9
221 functioning gonadotropic adenoma 9.9
222 osteoporotic fracture 9.9
223 aortic aneurysm, familial abdominal, 1 9.8
224 atherosclerosis susceptibility 9.8
225 esophageal cancer 9.8
226 neutrophil migration 9.8
227 pernicious anemia 9.8
228 small cell cancer of the lung 9.8
229 tetralogy of fallot 9.8
230 tuberous sclerosis 1 9.8
231 lipoid congenital adrenal hyperplasia 9.8
232 cystic fibrosis 9.8
233 hemochromatosis, type 1 9.8
234 immunodeficiency-centromeric instability-facial anomalies syndrome 1 9.8
235 nijmegen breakage syndrome 9.8
236 osteogenic sarcoma 9.8
237 pancreatic cancer 9.8
238 polycythemia vera 9.8
239 nance-horan syndrome 9.8
240 retinitis pigmentosa 2 9.8
241 wilms tumor 5 9.8
242 leukemia, acute myeloid 9.8
243 yemenite deaf-blind hypopigmentation syndrome 9.8
244 alzheimer disease 5 9.8
245 hemophagocytic lymphohistiocytosis, familial, 2 9.8
246 cervical cancer 9.8
247 salla disease 9.8
248 macrocephaly/autism syndrome 9.8
249 nasopharyngeal carcinoma 9.8
250 endometrial cancer 9.8
251 myocardial infarction 9.8
252 major depressive disorder 9.8
253 avascular necrosis of femoral head, primary, 1 9.8
254 acute promyelocytic leukemia 9.8
255 lung cancer susceptibility 3 9.8
256 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.8
257 wilms tumor 6 9.8
258 deficiency anemia 9.8
259 peyronie's disease 9.8
260 bone fracture 9.8
261 diffuse large b-cell lymphoma 9.8
262 glomerulonephritis 9.8
263 ischemic heart disease 9.8
264 male infertility 9.8
265 spinal cord injury 9.8
266 familial adenomatous polyposis 9.8
267 hemorrhagic cystitis 9.8
268 large cell neuroendocrine carcinoma 9.8
269 thrombosis 9.8
270 nonalcoholic fatty liver disease 9.8
271 anthracosis 9.8
272 hydronephrosis 9.8
273 chlamydia 9.8
274 cardiac tamponade 9.8
275 pure red-cell aplasia 9.8
276 tuberous sclerosis 9.8
277 obstructive jaundice 9.8
278 facial paralysis 9.8
279 interstitial cystitis 9.8
280 thrombocytopenia due to platelet alloimmunization 9.8
281 mental depression 9.8
282 thyroid cancer 9.8
283 bone cancer 9.8
284 leiomyosarcoma 9.8
285 acromegaly 9.8
286 kidney cancer 9.8
287 benign mesothelioma 9.8
288 transitional cell carcinoma 9.8
289 leydig cell tumor 9.8
290 endometriosis 9.8
291 pulmonary tuberculosis 9.8
292 lipomatosis 9.8
293 liposarcoma 9.8
294 periodontal disease 9.8
295 skin carcinoma 9.8
296 aortic aneurysm 9.8
297 lactic acidosis 9.8
298 bladder urothelial carcinoma 9.8
299 syphilis 9.8
300 spindle cell sarcoma 9.8
301 pustulosis of palm and sole 9.8
302 spindle cell hemangioma 9.8
303 infertility 9.8
304 paget's disease of bone 9.8
305 lymphopenia 9.8
306 bilateral breast cancer 9.8
307 compartment syndrome 9.8
308 herpes zoster 9.8
309 chickenpox 9.8
310 psoriasis 9.8
311 amyloidosis 9.8
312 fatty liver disease 9.8
313 polyarteritis nodosa 9.8
314 hypoglycemia 9.8
315 juvenile hereditary hemochromatosis 9.8
316 acquired hemophilia a 9.8
317 bowenoid papulosis 9.8
318 limbic encephalitis 9.8
319 microscopic polyangiitis 9.8
320 oral cancer 9.8
321 primary orthostatic tremor 9.8
322 retroperitoneal fibrosis 9.8
323 soft tissue sarcoma 9.8
324 multiple endocrine neoplasia 9.8
325 myoclonus 9.8
326 foot drop 9.8
327 autosomal recessive epidermolytic ichthyosis 9.8
328 acanthosis nigricans 9.7
329 alcohol dependence 9.7
330 anal canal carcinoma 9.7
331 arteries, anomalies of 9.7
332 autoimmune disease 9.7
333 blood group, kidd system 9.7
334 blood group system, landsteiner-wiener 9.7
335 diabetes insipidus, nephrogenic, autosomal 9.7
336 multiple endocrine neoplasia, type i 9.7
337 esterase c 9.7
338 glioma susceptibility 1 9.7
339 holt-oram syndrome 9.7
340 endosteal hyperostosis, autosomal dominant 9.7
341 ige responsiveness, atopic 9.7
342 laryngeal adductor paralysis 9.7
343 lichen sclerosus et atrophicus 9.7
344 li-fraumeni syndrome 9.7
345 melanoma, cutaneous malignant 2 9.7
346 antigen defined by monoclonal antibody aj9 9.7
347 paget disease of bone 3 9.7
348 pheochromocytoma 9.7
349 porphyria, acute intermittent 9.7
350 premature chromatid separation trait 9.7
351 smith-magenis syndrome 9.7
352 thrombophilia due to thrombin defect 9.7
353 ureterocele 9.7
354 renal hypodysplasia/aplasia 1 9.7
355 vertical talus, congenital 9.7
356 ascites, chylous 9.7
357 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.7
358 fanconi anemia, complementation group a 9.7
359 indifference to pain, congenital, autosomal recessive 9.7
360 intracranial hypertension, idiopathic 9.7
361 myelofibrosis 9.7
362 3-methylglutaconic aciduria, type iii 9.7
363 pulmonary alveolar microlithiasis 9.7
364 testicular germ cell tumor 9.7
365 squamous cell carcinoma, head and neck 9.7
366 testicular germ cell tumor 1 9.7
367 pigmentary disorder, reticulate, with systemic manifestations, x-linked 9.7
368 androgen insensitivity, partial 9.7
369 retinal dysplasia, primary 9.7
370 taqi polymorphism 9.7
371 ataxia and polyneuropathy, adult-onset 9.7
372 myoclonic epilepsy associated with ragged-red fibers 9.7
373 oncocytoma 9.7
374 exstrophy of bladder 9.7
375 retinitis pigmentosa 13 9.7
376 gallbladder disease 1 9.7
377 asthma 9.7
378 stroke, ischemic 9.7
379 blood group--swann system 9.7
380 macular degeneration, age-related, 1 9.7
381 lymphoma, non-hodgkin, familial 9.7
382 basal cell carcinoma 1 9.7
383 pulmonary disease, chronic obstructive 9.7
384 coronary heart disease 1 9.7
385 autoimmune disease 1 9.7
386 aural atresia, congenital 9.7
387 fanconi anemia, complementation group j 9.7
388 aplastic anemia 9.7
389 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.7
390 ewing sarcoma 9.7
391 pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis 9.7
392 alpha-2-macroglobulin deficiency 9.7
393 lactate dehydrogenase b deficiency 9.7
394 membranous nephropathy 9.7
395 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.7
396 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 9.7
397 glucocorticoid resistance, generalized 9.7
398 blood group, dombrock system 9.7
399 peripheral vascular disease 9.7
400 angina pectoris 9.7
401 pulmonary hypertension 9.7
402 acute liver failure 9.7
403 brain meningioma 9.7
404 cataract 9.7
405 chromophobe renal cell carcinoma 9.7
406 chronic kidney failure 9.7
407 common variable immunodeficiency 9.7
408 coronary artery anomaly 9.7
409 crohn's disease 9.7
410 gas gangrene 9.7
411 liver cirrhosis 9.7
412 mantle cell lymphoma 9.7
413 muscle disorders 9.7
414 osteoarthritis 9.7
415 angiosarcoma 9.7
416 exanthem 9.7
417 persistent mullerian duct syndrome 9.7
418 adrenal gland pheochromocytoma 9.7
419 aphasia 9.7
420 pain agnosia 9.7
421 atrial fibrillation 9.7
422 ectopic cushing syndrome 9.7
423 fibrous dysplasia 9.7
424 bladder exstrophy-epispadias-cloacal exstrophy complex 9.7
425 desmoid tumor 9.7
426 castleman disease 9.7
427 cholelithiasis 9.7
428 prolymphocytic leukemia 9.7
429 microinvasive gastric cancer 9.7
430 glucose intolerance 9.7
431 lactose intolerance 9.7
432 malignant hypertension 9.7
433 abducens nerve disease 9.7
434 brucellosis 9.7
435 q fever 9.7
436 pertussis 9.7
437 respiratory failure 9.7
438 primary hyperparathyroidism 9.7
439 arteriovenous malformation 9.7
440 hemopericardium 9.7
441 cauda equina syndrome 9.7
442 pericardial effusion 9.7
443 cortical blindness 9.7
444 nephrotic syndrome 9.7
445 osteopoikilosis 9.7
446 allergic hypersensitivity disease 9.7
447 hemosiderosis 9.7
448 neurogenic bladder 9.7
449 lymphocytic choriomeningitis 9.7
450 prostatocystitis 9.7
451 secondary hyperparathyroidism 9.7
452 paracoccidioidomycosis 9.7
453 quadriplegia 9.7
454 uveitis 9.7
455 acute cystitis 9.7
456 diarrhea 9.7
457 porphyria 9.7
458 color blindness 9.7
459 urethritis 9.7
460 coccidioidomycosis 9.7
461 cholestasis 9.7
462 polyneuropathy 9.7
463 acquired color blindness 9.7
464 schistosomiasis 9.7
465 bacteriuria 9.7
466 azoospermia 9.7
467 sclerosing cholangitis 9.7
468 seminal vesicle adenocarcinoma 9.7
469 papilledema 9.7
470 cholera 9.7
471 panniculitis 9.7
472 urticaria 9.7
473 lymphadenitis 9.7
474 keratosis 9.7
475 pneumothorax 9.7
476 hepatitis c 9.7
477 malignant fibroxanthoma 9.7
478 post-traumatic stress disorder 9.7
479 constipation 9.7
480 nocardiosis 9.7
481 colon adenocarcinoma 9.7
482 arteriosclerosis 9.7
483 myelophthisic anemia 9.7
484 granular cell tumor 9.7
485 basal cell carcinoma 9.7
486 orchitis 9.7
487 agammaglobulinemia 9.7
488 dermatitis 9.7
489 bilirubin metabolic disorder 9.7
490 melancholia 9.7
491 glioblastoma multiforme 9.7
492 astrocytoma 9.7
493 inverted papilloma 9.7
494 complex regional pain syndrome 9.7
495 thymic carcinoma 9.7
496 embryonal carcinoma 9.7
497 mood disorder 9.7
498 bone inflammation disease 9.7
499 fibrosarcoma 9.7
500 breast adenocarcinoma 9.7
501 cellulitis 9.7
502 choriocarcinoma 9.7
503 plexopathy 9.7
504 plasmacytoma 9.7
505 hermansky-pudlak syndrome 9.7
506 linitis plastica 9.7
507 hypertrichosis 9.7
508 myopathy 9.7
509 histiocytoma 9.7
510 carcinosarcoma 9.7
511 granulomatous dermatitis 9.7
512 fibrous histiocytoma 9.7
513 cutaneous fibrous histiocytoma 9.7
514 seminoma 9.7
515 hypokalemia 9.7
516 pleomorphic adenoma 9.7
517 brain edema 9.7
518 pancreatitis 9.7
519 pituitary gland disease 9.7
520 pulmonary coin lesion 9.7
521 functioning pituitary adenoma 9.7
522 testicular germ cell cancer 9.7
523 kidney disease 9.7
524 large intestine cancer 9.7
525 cribriform carcinoma 9.7
526 cowden syndrome 9.7
527 bone lymphoma 9.7
528 pseudosarcomatous fibromatosis 9.7
529 monoclonal gammopathy of uncertain significance 9.7
530 peritonitis 9.7
531 localized scleroderma 9.7
532 hypopharynx cancer 9.7
533 evans' syndrome 9.7
534 parotid gland cancer 9.7
535 peliosis hepatis 9.7
536 submandibular gland cancer 9.7
537 urethral diverticulum 9.7
538 epididymo-orchitis 9.7
539 hypopituitarism 9.7
540 diabetes insipidus 9.7
541 intracranial hypertension 9.7
542 cholangitis 9.7
543 pulmonary embolism 9.7
544 necrotizing fasciitis 9.7
545 tenosynovitis 9.7
546 irritable bowel syndrome 9.7
547 hydrocele 9.7
548 acute respiratory distress syndrome 9.7
549 amaurosis fugax 9.7
550 anterior uveitis 9.7
551 biliary tract cancer 9.7
552 bone marrow necrosis 9.7
553 brainstem auditory evoked responses 9.7
554 carcinoid syndrome 9.7
555 carcinoma showing thymus-like differentiation 9.7
556 cerebellar degeneration 9.7
557 chromosome 8p deletion 9.7
558 chronic thromboembolic pulmonary hypertension 9.7
559 degos 'en cocarde' erythrokeratoderma 9.7
560 dendritic cell tumor 9.7
561 desmoplastic infantile astrocytoma 9.7
562 fournier gangrene 9.7
563 germ cells tumors 9.7
564 glioma 9.7
565 hansen's disease 9.7
566 hypertrichosis lanuginosa, acquired 9.7
567 mediastinal endodermal sinus tumors 9.7
568 mycetoma 9.7
569 opsoclonus-myoclonus syndrome 9.7
570 streptococcal group a invasive disease 9.7
571 t-cell prolymphocytic leukemia 9.7
572 undifferentiated pleomorphic sarcoma 9.7
573 unicentric castleman disease 9.7
574 color vision deficiency 9.7
575 paraneoplastic syndromes 9.7
576 seizure disorder 9.7
577 tremor 9.7
578 headache 9.7
579 pouchitis 9.7
580 primary bone lymphoma 9.7
581 silent pituitary adenoma 9.7
582 xq12-q13.3 duplication syndrome 9.7
583 paraneoplastic pemphigus 9.7
584 myxofibrosarcoma 9.7
585 non-functioning pituitary adenoma 9.7

Graphical network of the top 20 diseases related to Prostate Cancer, Hereditary, 8:



Diseases related to Prostate Cancer, Hereditary, 8

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 8

Clinical features from OMIM:

602759

Drugs & Therapeutics for Prostate Cancer, Hereditary, 8

Search Clinical Trials , NIH Clinical Center for Prostate Cancer, Hereditary, 8

Genetic Tests for Prostate Cancer, Hereditary, 8

Anatomical Context for Prostate Cancer, Hereditary, 8

MalaCards organs/tissues related to Prostate Cancer, Hereditary, 8:

42
Prostate, Bone, Lymph Node, Endothelial, Testes, T Cells, Pituitary

Publications for Prostate Cancer, Hereditary, 8

Articles related to Prostate Cancer, Hereditary, 8:

(showing 22365, show less)
# Title Authors Year
1
Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review. ( 31081296 )
2019
2
Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. ( 30782054 )
2019
3
Depression and prostate cancer: A focused review for the clinician. ( 30630735 )
2019
4
Hypoxia Patterns in Primary and Metastatic Prostate Cancer Environments. ( 30639975 )
2019
5
Inflammatory Bowel Disease and the Risk of Prostate Cancer. ( 30528221 )
2019
6
Synthesis and Evaluation of Multifunctional Fluorescent Inhibitors with Synergistic Interaction of Prostate-Specific Membrane Antigen and Hypoxia for Prostate Cancer. ( 30485073 )
2019
7
Resveratrol integrates metabolic and growth effects in PC3 prostate cancer cells-involvement of prolyl hydroxylase and hypoxia inducible factor-1. ( 30655819 )
2019
8
Hypoxia and angiogenic biomarkers in prostate cancer after external beam radiotherapy (EBRT) alone or combined with high-dose-rate brachytherapy boost (HDR-BTb). ( 31059955 )
2019
9
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents. ( 31065911 )
2019
10
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells. ( 31016228 )
2019
11
A Rare Case of Liver Metastasis from Prostate Cancer Mimicking Hepatocellular Carcinoma on Immunohistochemistry: Role of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Diagnosis. ( 30713383 )
2019
12
Nuclear FGFR2 negatively regulates hypoxia-induced cell invasion in prostate cancer by interacting with HIF-1 and HIF-2. ( 30837551 )
2019
13
Rapid resolution of prostate cancer-related hemolytic uremic syndrome without plasma exchange - a case report. ( 31085156 )
2019
14
Statins Use and the Risk of Prostate Cancer in Ischemic Heart Disease Patients in Taiwan. ( 30801679 )
2019
15
Malignant jejunal gastrointestinal stromal tumor with history of prostate cancer: A case report. ( 31045773 )
2019
16
A case of synchronous advanced gastric cancer and locally advanced prostate cancer with combined laparoscopic and robotic surgery: A case report. ( 30852372 )
2019
17
Deciphering the scalene association among type-2 diabetes mellitus, prostate cancer, and chronic myeloid leukemia via enrichment analysis of disease-gene network. ( 30938105 )
2019
18
Educational level and the risk of depression after prostate cancer. ( 30700197 )
2019
19
Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy. ( 30748008 )
2019
20
Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy: A psychological perspective. ( 30747996 )
2019
21
Spirit-Quieting Traditional Chinese Medicine may Improve Survival in Prostate Cancer Patients with Depression. ( 30744039 )
2019
22
Re: Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer. ( 31101535 )
2019
23
Prognostic Significance of Sites of Visceral Metastatic Disease in Prostate Cancer: A Population-based Study of 12,180 Patients. ( 31101579 )
2019
24
Prostate cancer in sexual minorities and the influence of HIV status. ( 31101896 )
2019
25
Multiparametric magnetic resonance imaging prior to radical prostatectomy identifies intraductal and cribriform growth pattern of prostate cancer. ( 31102571 )
2019
26
Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer. ( 31103335 )
2019
27
Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer. ( 31103340 )
2019
28
NICE guidance on enzalutamide for non-metastatic, hormone-relapsed prostate cancer. ( 31103426 )
2019
29
Management of Prostate Cancer Patients with Clinically Positive Lymph Nodes. ( 31103720 )
2019
30
Multiparametric MRI - local staging of prostate cancer and beyond. ( 31103999 )
2019
31
Targeting prostate cancer cell proliferation, stemness and metastatic potential using Costus speciosus derived phytochemicals. ( 31105862 )
2019
32
The human positive cofactor 4 promotes androgen-independent prostate cancer development and progression through HIF-1α/β-catenin pathway. ( 31105996 )
2019
33
African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. ( 31107158 )
2019
34
Comparative Effectiveness of All Available Treatments for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-analysis. ( 31107252 )
2019
35
In Organ-confined Prostate Cancer, Tumor Quantitation Not Found to Aid in Prediction of Biochemical Recurrence. ( 31107718 )
2019
36
Effects of diabetes mellitus and Metformin administration on prostate cancer detection at biopsy among Chinese men: a case-control study. ( 30941974 )
2019
37
Testosterone Levels and Sexual Quality of Life Following Stereotactic Body Radiotherapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials. ( 31108142 )
2019
38
Re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028. ( 31109815 )
2019
39
Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer. ( 31109836 )
2019
40
BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK. ( 31110158 )
2019
41
Does early depressive mood expire following radical retropubic prostatectomy in patients with localized prostate cancer? ( 31111011 )
2019
42
Correction to: 3D skeletal uptake of 18F sodium fluoride in PET/CT images is associated with overall survival in patients with prostate cancer. ( 31111337 )
2019
43
Androgen deprivation therapy and the risk of tenosynovitis in prostate cancer patients. ( 31111393 )
2019
44
CUL4B regulates cancer stem-like traits of prostate cancer cells by targeting BMI1 via miR200b/c. ( 31111526 )
2019
45
The relationship between androgen deprivation therapy and depression symptoms in patients with prostate cancer. ( 30651026 )
2019
46
Personalized risks of overdiagnosis for screen-detected prostate cancer incorporating patient comorbidities: Estimation and communication. ( 31112106 )
2019
47
Behavior Issues, Skin Cancer, Adolescent Depression, Prostate Cancer, Deprescribing Antipsychotics. ( 30702247 )
2019
48
Re: Rano Matta, Christopher J.D. Wallis, Mitchell G. Goldenberg, et al. Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study. Eur Urol 2019;75:3-7: Translational Potential of Dual Detection: Depression Diagnosis plus Sense of Coherence Determination in Prostate Cancer. ( 30732926 )
2019
49
Patterns and predictors of self-reported clinical diagnosis and treatment for depression in prostate cancer survivors. ( 31106980 )
2019
50
Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer. ( 30337635 )
2019
51
Androgen deprivation therapy for prostate cancer and risk of dementia. ( 30637900 )
2019
52
Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.002. ( 31080125 )
2019
53
Peimine inhibits the growth and motility of prostate cancer cells and induces apoptosis by disruption of intracellular calcium homeostasis through Ca2+ /CaMKII/JNK pathway. ( 31081133 )
2019
54
Editorial Comment to Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes. ( 31081158 )
2019
55
Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review. ( 31081297 )
2019
56
Applying a variable relative biological effectiveness (RBE) might affect the analysis of clinical trials comparing photon and proton therapy for prostate cancer. ( 31082810 )
2019
57
Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review. ( 31083254 )
2019
58
Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death. ( 31083651 )
2019
59
PSMA-ligand PET allows a more accurate therapeutic response evaluation of bone metastases in prostate cancer compared to computed tomography. ( 31083752 )
2019
60
Multi-parametric MRI-based radiomics signature for discriminating between clinically significant and insignificant prostate cancer: Cross-validation of a machine learning method. ( 31084754 )
2019
61
Prostate Cancer National Summit's Call to Action. ( 31085057 )
2019
62
Aneuploidy drives lethal progression in prostate cancer. ( 31085648 )
2019
63
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. ( 31085757 )
2019
64
Germline and Somatic Mutations in Prostate Cancer for the Clinician. ( 31085765 )
2019
65
In vivo transrectal imaging of canine prostate with a sensitive and compact handheld transrectal array photoacoustic probe for early diagnosis of prostate cancer. ( 31086699 )
2019
66
Fiducial markers in prostate cancer image-guided radiotherapy. ( 31086794 )
2019
67
Editorial Comment to How does 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery? ( 31087465 )
2019
68
MicroRNA-107 inhibits proliferation of prostate cancer cells by targeting cyclin E1. ( 31088102 )
2019
69
Supernatant Metabolites from Halophilic Archaea to Reduce Tumorigenesis in Prostate Cancer In-vitro and In-vivo. ( 31089359 )
2019
70
SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer. ( 31090082 )
2019
71
Circulating Estrogen Receptor Mutations and Splice Variants in Advanced Prostate Cancer. ( 31090242 )
2019
72
Prostate cancer risk by occupation in the Occupational Disease Surveillance System (ODSS) in Ontario, Canada. ( 31091061 )
2019
73
More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. ( 31091399 )
2019
74
More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. Reply. ( 31091400 )
2019
75
Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA). ( 31092276 )
2019
76
Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO). ( 31092381 )
2019
77
A rare case of tumor-to-tumor metastasis: Prostate cancer to chromophobe renal cell carcinoma. ( 30505689 )
2019
78
The Epigenetic Modifier 5-Aza-2-deoxycytidine Triggers the Expression of CD146 Gene in Prostate Cancer Cells. ( 31092432 )
2019
79
Quantification of Bone Metastasis of Castration-resistant Prostate Cancer After Enzalutamide and Abiraterone Acetate Using Bone Scan Index on Bone Scintigraphy. ( 31092452 )
2019
80
The PHLPP2 phosphatase is a druggable driver of prostate cancer progression. ( 31092557 )
2019
81
Author Correction: Automated Gleason grading of prostate cancer tissue microarrays via deep learning. ( 31092857 )
2019
82
A new era: artificial intelligence and machine learning in prostate cancer. ( 31092914 )
2019
83
Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation. ( 31094098 )
2019
84
Depression Stresses the Immune Response and Promotes Prostate Cancer Growth. ( 30670491 )
2019
85
Chlamydia trachomatis Growth and Cytokine mRNA Response in a Prostate Cancer Cell Line. ( 30800160 )
2019
86
The Role of Primary Tumor Treatment and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer. ( 31095719 )
2019
87
Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why. ( 31096849 )
2019
88
Multiparametric magnetic resonance imaging-transrectal ultrasound fusion biopsies increase the rate of cancer detection in populations with a low incidence of prostate cancer. ( 31098422 )
2019
89
Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor. ( 31079810 )
2019
90
Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study. ( 31098427 )
2019
91
Letter to the editor: Changes in health-related quality of life after radical prostatectomy for prostate cancer: A longitudinal cohort study in Korea. ( 31098431 )
2019
92
Targeted Notch1 inhibition with a Notch1 antibody, OMP-A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression. ( 31099068 )
2019
93
All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care. ( 31099647 )
2019
94
Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28. ( 30503180 )
2019
95
The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer. ( 31099673 )
2019
96
Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28: Radiation Therapy Versus Radical Prostatectomy: No Way Out Without a Randomized Trial. ( 30502105 )
2019
97
Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28. ( 30473434 )
2019
98
Androgen receptor in breast cancer: a wolf in sheep's clothing? A lesson from prostate cancer. ( 31002873 )
2019
99
A Comparative Study of Google Search Trends for Melanoma, Breast Cancer and Prostate Cancer in Finland. ( 30999301 )
2019
100
A Synchronous Diagnosis of Metastatic Male Breast Cancer and Prostate Cancer. ( 31053047 )
2019
101
Inflammatory mediators of prostate epithelial cells stimulated with Trichomonas vaginalis promote proliferative and invasive properties of prostate cancer cells. ( 31050003 )
2019
102
Salvage Cryoablation for Radiorecurrent Prostate Cancer: Initial Experience at a Regional Health Care System. ( 31050644 )
2019
103
Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer. ( 31051242 )
2019
104
Consecutive Prostate Cancer Specimens Revealed Increased Aldo⁻Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer. ( 31052459 )
2019
105
A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer. ( 31053137 )
2019
106
Focal therapy for localized prostate cancer: Where do we stand? ( 31053567 )
2019
107
Aspirin and Prostate Cancer Incidence and Mortality-Letter. ( 31053637 )
2019
108
A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor. ( 31053749 )
2019
109
Preclinical assessment of 68 Ga-PSMA-617 entrapped in a microemulsion delivery system for applications in prostate cancer PET/CT imaging. ( 31054157 )
2019
110
Light-activated ruthenium (II)-bicalutamide prodrugs for prostate cancer. ( 31054419 )
2019
111
Tissue-specific quantification and localization of androgen and estrogen receptors in prostate Cancer. ( 31054895 )
2019
112
Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer. ( 31055874 )
2019
113
Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes. ( 31055879 )
2019
114
Re: Optimizing Patient's Selection for Prostate Biopsy: A Single Institution Experience with Multi-parametric MRI and the 4Kscore Test for the Detection of Aggressive Prostate Cancer. ( 31056230 )
2019
115
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. ( 31056399 )
2019
116
The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals? ( 31056436 )
2019
117
Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer. ( 31058923 )
2019
118
Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy. ( 31059665 )
2019
119
Overactive Surveillance: Is "Conservative" Management for Low-risk Prostate Cancer Too Aggressive? ( 31060823 )
2019
120
What are the limits of focal therapy for localized prostate cancer? For: GG3-5 may be considered. ( 31060852 )
2019
121
Genomic correlates of clinical outcome in advanced prostate cancer. ( 31061129 )
2019
122
KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells. ( 31061526 )
2019
123
Prostate cancer: On the road of progress. ( 31061796 )
2019
124
Contemporary approach to active surveillance for favorable risk prostate cancer. ( 31061800 )
2019
125
Systemic treatment for metastatic prostate cancer. ( 31061802 )
2019
126
Re: Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer. ( 31063054 )
2019
127
Re: Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. ( 31063059 )
2019
128
Re: A 17-Gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility. ( 31063064 )
2019
129
Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up. ( 31063072 )
2019
130
Artificial intelligence at the intersection of pathology and radiology in prostate cancer. ( 31063138 )
2019
131
Racial Disparities in Low-Risk Prostate Cancer. ( 31063566 )
2019
132
Racial Disparities in Low-Risk Prostate Cancer-Reply. ( 31063570 )
2019
133
Re: Felix Preisser, Felix K.H. Chun, Raisa S. Pompe, et al. Persistent Prostate-specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.01.048: Useful Prognostic Information in Prostate Cancer After Radical Prostatectomy Might Not Be Applicable to High-risk Disease. ( 31064693 )
2019
134
PGC-1α inhibits polyamine synthesis to suppress prostate cancer aggressiveness. ( 31064849 )
2019
135
Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men. ( 31065112 )
2019
136
External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. ( 30293908 )
2019
137
Information in radiotherapy for men with localised prostate cancer: An integrative review. ( 31066129 )
2019
138
Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28: Radiation Therapy Versus Radical Prostatectomy: No Way Out Without a Randomized Trial. ( 30509762 )
2019
139
The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer. ( 31067013 )
2019
140
High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis. ( 30666156 )
2019
141
Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer. ( 30903422 )
2019
142
BRCAness in prostate cancer. ( 31069005 )
2019
143
177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer. ( 31069008 )
2019
144
Psychological distress among prostate cancer survivors in South Korea: A nationwide population-based, longitudinal study. ( 31069946 )
2019
145
Bispecific Radioligands targeting Prostate Specific Membrane Antigen (PSMA) and Gastrin Releasing Peptide receptors (GRPr) on the surface of prostate cancer cells. ( 31070273 )
2019
146
Hemiablation of Localized Prostate Cancer by High-Intensity Focused Ultrasound: A Series of 35 Cases. ( 31071712 )
2019
147
Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS). ( 31072729 )
2019
148
Role of novel imaging in the management of prostate cancer. ( 31072791 )
2019
149
Functional Recovery Following Primary Treatment for Prostate Cancer: Update from the CEASAR Study. ( 31072805 )
2019
150
Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone + prednisone. ( 31073853 )
2019
151
Re: Systematic Review and Network Meta-Analysis on the Relative Efficacy of Osteoporotic Medications: Men with Prostate Cancer on Continuous Androgen-Deprivation Therapy to Reduce Risk of Fragility Fractures. ( 31075075 )
2019
152
Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. ( 31075528 )
2019
153
Alginate oligosaccharide attenuates α2,6-sialylation modification to inhibit prostate cancer cell growth via the Hippo/YAP pathway. ( 31076566 )
2019
154
Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. ( 31077523 )
2019
155
The Effect of Radiotherapy on the Concentration of Plasma Lipids in Elderly Prostate Cancer Patients. ( 31023130 )
2019
156
Correction to: Automatically identifying social isolation from clinical narratives for patients with prostate Cancer. ( 31023302 )
2019
157
Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience. ( 31023520 )
2019
158
Author Correction: Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits Tumour Development in TRAMP Mice. ( 31024014 )
2019
159
Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P. ( 31025290 )
2019
160
Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer prior to initial prostate biopsy. ( 31026217 )
2019
161
Examining trajectories of anxiety in men with prostate cancer faced with complex treatment decisions. ( 30014194 )
2019
162
Prostate cancer-specific anxiety and the resulting health-related quality of life in couples. ( 30132975 )
2019
163
Early Second Round Targeted Biopsy of PI-RADS Score 3 or 4 in 256 Men With Persistent Suspicion of Prostate Cancer. ( 31028214 )
2019
164
Parallel and serial mediation analysis between pain, anxiety, depression, fatigue and nausea, vomiting and retching within a randomised controlled trial in patients with breast and prostate cancer. ( 30679301 )
2019
165
DDR pathway mediates radiosensitization in prostate cancer. ( 31028368 )
2019
166
DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA. ( 31028426 )
2019
167
Establishing a common metric for self-reported anxiety in patients with prostate cancer: Linking the Memorial Anxiety Scale for Prostate Cancer with PROMIS Anxiety. ( 31090933 )
2019
168
Sexual Health Recovery For Prostate Cancer Survivors: The Proposed Role Of Acceptance And Mindfulness-Based Interventions. ( 31029619 )
2019
169
Interleukin-7 Contributes to the Invasiveness of Prostate Cancer Cells by Promoting Epithelial-Mesenchymal Transition. ( 31061414 )
2019
170
Recurrence in prostate cancer: salvage diagnostic and therapeutic strategies. ( 31030228 )
2019
171
Extracapsular extension on MRI indicates a more aggressive cell cycle progression genotype of prostate cancer. ( 31030245 )
2019
172
Prostate Cancer Screening. ( 31030827 )
2019
173
Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? ( 31031049 )
2019
174
Estimation of tumor and local tissue dose in gold nanoparticles radiotherapy for prostate cancer. ( 31031569 )
2019
175
Current Treatment for Low-Risk Prostate Cancer in China: A National Network Survey. ( 31031859 )
2019
176
Patient centered care for prostate cancer-how can artificial intelligence and machine learning help make the right decision for the right patient? ( 31032282 )
2019
177
Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction? ( 31032288 )
2019
178
Nanoparticles as theranostic vehicles in prostate cancer. ( 31032309 )
2019
179
Potential biological and clinical benefit of prostate-directed interventions in patients with metastatic prostate cancer. ( 31032325 )
2019
180
In Vivo 3D MRI Measurement of Tumour Volume in an Orthotopic Mouse Model of Prostate Cancer. ( 31032634 )
2019
181
Rapid Development of Spinal Epidural Lipomatosis after Treatment of Metastatic Castration-resistant Prostate Cancer with Second-Generation Androgen Receptor Antagonists. ( 30763756 )
2019
182
Variable selection in semiparametric nonmixture cure model with interval-censored failure time data: An application to the prostate cancer screening study. ( 31032999 )
2019
183
Development of bispecific NT-PSMA heterodimer for prostate cancer imaging: a potential approach to address tumor heterogeneity. ( 31034212 )
2019
184
rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy. ( 31035590 )
2019
185
Genetic Polymorphism in Sex Hormone-binding Globulin With a Prognosis of Androgen Deprivation Therapy in Metastatic Prostate Cancer Among Japanese Men. ( 31036465 )
2019
186
Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer. ( 31036926 )
2019
187
Synergistic Effects of Nobiletin and Sorafenib Combination on Metastatic Prostate Cancer Cells. ( 31037974 )
2019
188
Second brazilian consensus on the treatment of advanced prostate cancer - a SBOC-SBU-SBRT panel review. ( 31038861 )
2019
189
Identifying quality of life indicators to improve outpatient pharmacy services for prostate cancer patients: a comparison between Brazilian and British experiences. ( 31038864 )
2019
190
Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study. ( 31039019 )
2019
191
Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer. ( 31039109 )
2019
192
Reconsideration on Clinical Benefit of Pelvic Lymph Node Dissection during Radical Prostatectomy for Clinically Localized Prostate Cancer. ( 31039571 )
2019
193
Targeting DLL3 in neuroendocrine prostate cancer. ( 31040438 )
2019
194
Evaluation of response in patients of metastatic castration resistant prostate cancer undergoing systemic radiotherapy with lutetium177-prostate-specific membrane antigen: A comparison between response evaluation criteria in solid tumors, positron-emission tomography response criteria in solid tumors, European organization for research and treatment of cancer, and MDA criteria assessed by gallium 68-prostate-specific membrane antigen positron-emission tomography-computed tomography. ( 31040600 )
2019
195
Extensive histological sampling following focal therapy of clinically significant prostate cancer with high-intensity focused ultrasound. ( 31042109 )
2019
196
Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells. ( 31042325 )
2019
197
SNW1 is a prognostic biomarker in prostate cancer. ( 31043167 )
2019
198
Retraction: Antitumor Effects of a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer. ( 31043388 )
2019
199
Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. ( 31043708 )
2019
200
Suicide Risk Associated with a Prostate Cancer Diagnosis ( 31044594 )
2019
201
Early use of abiraterone and radium-223 in metastatic prostate cancer. ( 31044705 )
2019
202
Early use of abiraterone and radium-223 in metastatic prostate cancer. ( 31044706 )
2019
203
Integrating PROMIS® computerized adaptive tests into a web-based intervention for prostate cancer. ( 31045423 )
2019
204
Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer. ( 31046065 )
2019
205
Prostate-Specific Membrane Antigen Positron Emission Tomography-Identified Para-aortic Prostate Cancer Recurrence After Surgery and Salvage Radiation Therapy. ( 31047622 )
2019
206
Responding to Information From Novel Positron Emission Tomography Imaging in Prostate Cancer. ( 31047623 )
2019
207
The Role of Splicing Regulators in the Emergence of Treatment-induced Neuroendocrine Prostate Cancer: The Next Generation of Drug Targets? ( 31047735 )
2019
208
Combined maternal and post-weaning high fat diet inhibits male offspring's prostate cancer tumorigenesis in transgenic adenocarcinoma of mouse prostate model. ( 30614041 )
2019
209
Preclinical toxicology and toxicokinetic evaluation of ailanthone, a natural product against castration-resistant prostate cancer, in mice. ( 31048010 )
2019
210
Correction: Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer. ( 31048775 )
2019
211
Prognostic Value of 18F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel. ( 31049043 )
2019
212
Polymeric Micellar Delivery of Novel Microtubule Destabilizer and Hedgehog Signaling Inhibitor for Treating Chemoresistant Prostate Cancer. ( 30996033 )
2019
213
BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. ( 30996246 )
2019
214
Chinese guidelines for diagnosis and treatment of prostate cancer 2018 (English version). ( 30996567 )
2019
215
Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression. ( 30996687 )
2019
216
Race and overall survival in men diagnosed with prostate cancer in the Department of Defense Military Health System, 1990-2010. ( 30997591 )
2019
217
Loss of Notch1 activity inhibits prostate cancer growth and metastasis and sensitizes prostate cancer cells to anti-androgen therapies. ( 31028097 )
2019
218
Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence. ( 30998834 )
2019
219
Erratum: A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormonesensitive prostate cancer. ( 31000930 )
2019
220
Upregulation of MicroRNA-21 promotes tumorigenesis of prostate cancer cells by targeting KLF5. ( 31002531 )
2019
221
Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS). ( 31002955 )
2019
222
Targeting the Deubiquitinase STAMBPL1 Triggers Apoptosis in Prostate Cancer Cells by Promoting XIAP Degradation. ( 31004702 )
2019
223
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities. ( 31006810 )
2019
224
Erratum: Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors. ( 31007853 )
2019
225
Interactions between Germline and Somatic Mutated Genes in Aggressive Prostate Cancer. ( 31007957 )
2019
226
External Validation of the Prostate Cancer-Specific Comorbidity Index (PCCI), a Claims-Based Tool for Prediction of Life Expectancy in Men with Prostate Cancer. ( 31009286 )
2019
227
Poly(I:C)-Mediated Death of Human Prostate Cancer Cell Lines Is Induced by Interleukin-27 Treatment. ( 31009295 )
2019
228
Separating the Dreadful from the Merely Bad: Towards Prognostic and Predictive Biomarkers in Metastatic Castration-resistant Prostate Cancer. ( 31010599 )
2019
229
Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer. ( 31011679 )
2019
230
Home-based exergaming was safe and significantly improved 6-min walking distance in prostate cancer patients: a single-blinded randomized controlled trial. ( 31012238 )
2019
231
Quality of life among patients after cystoprostatectomy as the treatment for locally advanced prostate cancer with bladder invasion. ( 31012363 )
2019
232
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer. ( 31012963 )
2019
233
A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges. ( 31013716 )
2019
234
Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy. ( 31013891 )
2019
235
Prostate cancer solitary metastasis to anal canal: case report and review of literature. ( 31014272 )
2019
236
Informed decision-making based on a leaflet in the context of prostate cancer screening. ( 31014933 )
2019
237
Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study. ( 31015158 )
2019
238
Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells. ( 30771432 )
2019
239
Where to Next for Theranostics in Prostate Cancer? ( 31017092 )
2019
240
Re: Ronald D. Ennis, Liangyuan Hu, Shannon N. Ryemon, Joyce Lin, Madhu Mazumdar. Brachytherapy-based Radiotherapy and Radical Prostatectomy Are Associated with Similar Survival in High-risk Localized Prostate Cancer. J Clin Oncol 2018;36:1192-8: Comparative Survival Analyses of Radical Prostatectomy and Radiation Therapy Reveal the Importance of Adequate Follow-up Time. ( 31017100 )
2019
241
Reply to Marieke J. Krimphove, Junaid Nabi, Alexander P. Cole, and Quoc-Dien Trinh's Letter to the Editor re: Ronald D. Ennis, Liangyuan Hu, Shannon N. Ryemon, Joyce Lin, Madhu Mazumdar. Brachytherapy-based Radiotherapy and Radical Prostatectomy Are Associated with Similar Survival in High-risk Localized Prostate Cancer. J Clin Oncol 2018;36:1192-8: Setting the Standard: The Importance of Defining the Standard of Care for Comparative Effectiveness Analyses. ( 31017101 )
2019
242
Reply to Marieke J. Krimphove, Junaid Nabi, Alexander P. Cole, and Quoc-Dien Trinh's Letter to the Editor re: Ronald D. Ennis, Liangyuan Hu, Shannon N. Ryemon, Joyce Lin, Madhu Mazumdar. Brachytherapy-based Radiotherapy and Radical Prostatectomy Are Associated with Similar Survival in High-risk Localized Prostate Cancer. J Clin Oncol 2018;36:1192-8. ( 31017102 )
2019
243
Piperine blocks voltage gated K+ current and inhibits proliferation in androgen sensitive and insensitive human prostate cancer cell lines. ( 31047869 )
2019
244
Kallikarein-related peptidase 3 common genetic variant and the risk of prostate cancer. ( 31017705 )
2019
245
IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2. ( 31020420 )
2019
246
Establishment and characterization of a prostate cancer cell line from a prostatectomy specimen for the study of cellular interaction. ( 31020641 )
2019
247
Super active surveillance for low-risk prostate cancer | Opinion: No. ( 31021585 )
2019
248
Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. ( 31022301 )
2019
249
Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer. ( 30964293 )
2019
250
Erratum to: Wilkins AC, Gusterson B, Szijgyarto Z, et al. Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2018;101:309-315. ( 30967236 )
2019
251
STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer? ( 30967237 )
2019
252
The prognostic value of zonal origin and extraprostatic extension of prostate cancer for biochemical recurrence after radical prostatectomy. ( 30967332 )
2019
253
Mini Review on the Use of Clinical Cancer Registers for Prostate Cancer: The National Prostate Cancer Register (NPCR) of Sweden. ( 30968024 )
2019
254
Symmetric breasts metastatic prostate cancer shown by 68Ga-PSMA PET/CT scan. ( 30968861 )
2019
255
BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype. ( 30968962 )
2019
256
Prostate cancer: molecular and cellular mechanisms and their implications in therapy resistance and disease progression. ( 30971530 )
2019
257
Herceptin-conjugated liposomes co-loaded with doxorubicin and simvastatin in targeted prostate cancer therapy. ( 30972160 )
2019
258
Comparison of relative and absolute rectal dose-volume parameters and clinical correlation with acute and late radiation proctitis in prostate cancer patients. ( 30191285 )
2019
259
Prostate cancer detection using residual networks. ( 30972686 )
2019
260
Effects of dihydroartemisinin on HSP70 expression in human prostate cancer PC-3 cells. ( 30972796 )
2019
261
TGF-β/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer. ( 30973040 )
2019
262
Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel. ( 30974114 )
2019
263
Solid Science for the Upside but Lack of Solid Science for the Downside-Towards Cutting-edge Prostate-cancer Screening. ( 30975451 )
2019
264
Salvage lymph node dissection in patients with prostate cancer treated with radical prostatectomy or radiotherapy and positive choline positron emission tomography (PET/CT) scan. ( 30975547 )
2019
265
Prognostic value of neutrophil-to-lymphocyte ratio in castration resistant prostate cancer: Single-centre study of Nigerian men. ( 30975955 )
2019
266
Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer. ( 30976180 )
2019
267
The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. ( 30977383 )
2019
268
NF-κB inhibition promotes apoptosis in androgen-independent prostate cancer cells by the photothermal effect via the IκBα/AR signaling pathway. ( 30977484 )
2019
269
Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer. ( 30978937 )
2019
270
A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer. ( 30979820 )
2019
271
Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer? ( 30980025 )
2019
272
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients. ( 30980027 )
2019
273
Synergistic effects of hormone therapy drugs and usnic acid on hormone receptor-positive breast and prostate cancer cells. ( 30980508 )
2019
274
LncRNA SNHG15 acts as an oncogene in prostate cancer by regulating miR-338-3p/FKBP1A axis. ( 30981837 )
2019
275
Tumor protein D52 (isoform 3) interacts with and promotes peroxidase activity of Peroxiredoxin 1 in prostate cancer cells implicated in cell growth and migration. ( 30981892 )
2019
276
Erratum to "Prostate Osteoblast-Like Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer Patients". ( 30983921 )
2019
277
Asymptomatic Prostate Cancer Brain Metastases on 68Ga-PSMA PET/CT. ( 30985411 )
2019
278
Incidental Detection of a Radiation-Induced Soft-Tissue Sarcoma on 68Ga-PSMA PET/CT in a Patient Previously Treated for Prostate Cancer. ( 30985417 )
2019
279
The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer. ( 30986486 )
2019
280
In early prostate cancer, radical prostatectomy reduced mortality more than watchful waiting at 23 years. ( 30986834 )
2019
281
'I'm not a chance taker': A mixed methods exploration of factors affecting prostate cancer treatment decision-making. ( 30987436 )
2019
282
RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer. ( 30987640 )
2019
283
Re: Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial. ( 30987845 )
2019
284
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. ( 30987939 )
2019
285
Importance of early treatment in metastatic prostate cancer: a question of life or death. ( 30987940 )
2019
286
p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance. ( 31100478 )
2019
287
Cholesterol induces epithelial-to-mesenchymal transition of prostate cancer cells by suppressing degradation of EGFR through APMAP. ( 30987997 )
2019
288
Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. ( 30988096 )
2019
289
Author Correction: Prostate-specific extracellular vesicles as a novel biomarker in human prostate cancer. ( 30988318 )
2019
290
Prostate cancer biomarkers detection using nanoparticles based electrochemical biosensors. ( 31100601 )
2019
291
Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data. ( 31100964 )
2019
292
KMT9 Is an Epigenetic Writer That Controls Prostate Cancer Cell Growth. ( 31101631 )
2019
293
PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY. ( 31101746 )
2019
294
Identification of novel susceptibility loci and genes for prostate cancer risk: A transcriptome-wide association study in over 140,000 European descendants. ( 31101764 )
2019
295
Triple treatment of high-risk prostate cancer. A matched cohort study with up to 19 years follow-up comparing survival outcomes after triple treatment and treatment with hormones and radiotherapy. ( 30990112 )
2019
296
Novel poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, AZD2461, down-regulates VEGF and induces apoptosis in prostate cancer cells ( 31102368 )
2019
297
Men's experiences of recontact about a potential increased risk of prostate cancer due to Lynch Syndrome: "Just another straw on the stack". ( 30969465 )
2019
298
Microsatellite Instability May Predict Response to Sipuleucel-T in Patients With Prostate Cancer. ( 31015016 )
2019
299
Osteoporosis and prostate cancer; a 24-month prospective observational study during androgen deprivation therapy. ( 30777478 )
2019
300
Will Favourable Functional Results with Salvage Robot-assisted Laparoscopic Radical Prostatectomy Increase the Uptake of Primary Focal Therapy for Localised Prostate Cancer? ( 30979637 )
2019
301
Some black men may have more aggressive prostate cancer than scoring indicates. ( 30990896 )
2019
302
The Anti-Proliferation, Cycle Arrest and Apoptotic Inducing Activity of Peperomin E on Prostate Cancer PC-3 Cell Line. ( 30991627 )
2019
303
Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study. ( 31103337 )
2019
304
Midkine silencing enhances the anti-prostate cancer stem cell activity of the flavone apigenin: cooperation on signaling pathways regulated by ERK, p38, PTEN, PARP, and NF-κB. ( 30993586 )
2019
305
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer. ( 31103601 )
2019
306
Recent trends in prostate cancer in Canada. ( 30994922 )
2019
307
Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. ( 31103721 )
2019
308
Detection and Localization of Prostate Cancer at 3-T Multiparametric MRI Using PI-RADS Segmentation. ( 30995090 )
2019
309
Re: Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer. The Prostate. 2019;1-7. ( 30995357 )
2019
310
IL-8 protects prostate cancer cells from GSK-3β-induced oxidative stress by activating the mTOR signaling pathway. ( 31104320 )
2019
311
VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient. ( 30938627 )
2019
312
miR-148-3p and miR-152-3p synergistically regulate prostate cancer progression via repressing KLF4. ( 31104329 )
2019
313
Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. ( 31104332 )
2019
314
Increasing Utilization of Multi-Parametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance. ( 30940480 )
2019
315
Prostate cancer cell growth characteristics in serum and prostate-conditioned media from moderate-intensity exercise-trained healthy and tumor-bearing rats. ( 31105994 )
2019
316
LncRNA UCA1 acts as a sponge of miR-204 to up-regulate CXCR4 expression and promote prostate cancer progression. ( 30940776 )
2019
317
A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients. ( 31106513 )
2019
318
A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients. ( 30941562 )
2019
319
Cancer Drug Use in the Last Month of Life in Men With Castration-Resistant Prostate Cancer. ( 31107628 )
2019
320
Minimal-Invasive Robot-Assisted Image-Guided Resection of Prostate-Specific Membrane Antigen-Positive Lymph Nodes in Recurrent Prostate Cancer. ( 31107740 )
2019
321
The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA. ( 31107971 )
2019
322
Ent-Dihydrotucumanoic acid promotes apoptosis in PC-3 human prostate cancer cells. ( 30942164 )
2019
323
MicroRNA‑302a upregulation mediates chemo‑resistance in prostate cancer cells. ( 30942454 )
2019
324
Diffusion-weighted Imaging of Prostate Cancer: Revisiting Occam's Razor. ( 30942671 )
2019
325
Synthesis of Novel Tanshinone Derivatives for Treatment of Castration-resistant Prostate Cancer. ( 31108007 )
2019
326
Gold-caged copolymer nanoparticles as multimodal synergistic photodynamic/photothermal/chemotherapy platform against lethality androgen-resistant prostate cancer. ( 31108274 )
2019
327
Evaluation of biophysical as well as biochemical potential of curcumin and resveratrol during prostate cancer. ( 30943812 )
2019
328
High-dose-rate brachytherapy as monotherapy for prostate cancer: The impact of cellular repair and source decay. ( 31109870 )
2019
329
Long-Term Clinical Outcomes of Radical Prostatectomy versus Watchful Waiting in Localized Prostate Cancer Patients: A Systematic Review and Meta-Analysis. ( 31110967 )
2019
330
Combination of metformin and paclitaxel suppresses proliferation and induces apoptosis of human prostate cancer cells via oxidative stress and targeting the mitochondria-dependent pathway. ( 30944622 )
2019
331
MiR-455-5p Suppresses the Progression of Prostate Cancer by Targeting CCR5. ( 31111062 )
2019
332
Comparative analysis of p16 expression among African American and European American prostate cancer patients. ( 31111520 )
2019
333
Barriers to obtaining prostate multi-parametric magnetic resonance imaging in African-American men on active surveillance for prostate cancer. ( 31111654 )
2019
334
Impact of serious mental illness on the treatment and mortality of older patients with locoregional high-grade (nonmetastatic) prostate cancer: retrospective cohort analysis of 49 985 SEER-Medicare patients diagnosed between 2006 and 2013. ( 30945473 )
2019
335
Robust contour propagation using deep learning and image registration for online adaptive proton therapy of prostate cancer. ( 31111962 )
2019
336
Cost-Effectiveness of Active Surveillance, Radical Prostatectomy, and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial. ( 31112105 )
2019
337
Disparities in prostate cancer survival in Appalachian Kentucky: a population-based study. ( 31078134 )
2019
338
Multidisciplinary Team Meetings for Prostate Cancer Treatment: We Can Do Much Better in Daily Life. ( 31079102 )
2019
339
Recovery of pad-free continence in elderly men does not differ from younger men undergoing robot-assisted radical prostatectomy for aggressive prostate cancer. ( 31079187 )
2019
340
The Possibility of Preventive and Therapeutic Use of Green Tea Catechins in Prostate Cancer. ( 30947675 )
2019
341
Re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.011. ( 30948226 )
2019
342
Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up. ( 30948227 )
2019
343
First point-of-care PSA test for prostate cancer detection. ( 30948842 )
2019
344
Red Cell Distribution Width Predicts Prostate-Specific Antigen Response and Survival of Patients With Castration-Resistant Prostate Cancer Treated With Androgen Receptor Axis-Targeted Agents. ( 31080022 )
2019
345
Determinants of quality prostate cancer survivorship care across the primary and specialty care interface: Lessons from the Veterans Health Administration. ( 30950216 )
2019
346
Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer. ( 31080102 )
2019
347
The Role of Tumor Oxygenation Tested by Magnetic Resonance Imaging (MRI) in Prostate Cancer Grading. ( 30950457 )
2019
348
Simvastatin delays castration‑resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin‑1. ( 31081050 )
2019
349
Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case-control sets from EPIC. ( 30951192 )
2019
350
The targeting of MTDH by miR‑145‑5p or miR‑145‑3p is associated with prognosis and regulates the growth and metastasis of prostate cancer cells. ( 31081051 )
2019
351
Do Canadian Radiation Oncologists Consider Geriatric Assessment in the Decision-Making Process for Treatment of Patients 80 years and Older with Non-Metastatic Prostate Cancer? - National Survey. ( 30952518 )
2019
352
Overexpressing miR‑335 inhibits DU145 cell proliferation by targeting early growth response 3 in prostate cancer. ( 31081063 )
2019
353
Long noncoding RNA LUCAT1 promotes migration and invasion of prostate cancer cells by inhibiting KISS1 expression. ( 31081080 )
2019
354
Long noncoding RNA AFAP1-AS1 accelerates the proliferation and metastasis of prostate cancer via inhibiting RBM5 expression. ( 31081081 )
2019
355
Diagnostic Performance of ⁶⁸Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis. ( 31081294 )
2019
356
High Skp2 expression is associated with a mesenchymal phenotype and increased tumorigenic potential of prostate cancer cells. ( 30952903 )
2019
357
Internet information on focal prostate cancer therapy: help or hindrance? ( 30952966 )
2019
358
Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer. ( 31081533 )
2019
359
Beliefs that contribute to delays in diagnosis of prostate cancer among Afro-Caribbean men in Trinidad and Tobago. ( 30953381 )
2019
360
Molecular imaging of the prostate: Comparing total sodium concentration quantification in prostate cancer and normal tissue using dedicated 13 C and 23 Na endorectal coils. ( 31081564 )
2019
361
Attention to the principles of exercise training in exercise studies on prostate cancer survivors: a systematic review. ( 30953460 )
2019
362
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. ( 31082669 )
2019
363
PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers. ( 30954315 )
2019
364
Single-fraction brachytherapy as monotherapy for early-stage prostate cancer: The UCSF experience. ( 30954399 )
2019
365
Treating the primary in metastatic prostate cancer: where do we stand? ( 31082943 )
2019
366
Deoxynivalenol Modulates the Viability, ROS Production and Apoptosis in Prostate Cancer Cells. ( 31083547 )
2019
367
How does 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery? ( 31083784 )
2019
368
Is it worth to perform salvage radical prostatectomy for radio-recurrent prostate cancer? A literature review. ( 30955047 )
2019
369
The correlation between metastasis-free survival and overall survival in non-metastatic castration resistant prostate cancer (nmCRPC) patients from the MDV claims database in Japan. ( 31084438 )
2019
370
Multi-parametric MRI tumor probability model for the detection of locally recurrent prostate cancer after radiotherapy: pathological validation and comparison with manual tumor delineations. ( 31085288 )
2019
371
Re: 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. ( 30955971 )
2019
372
Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up. ( 30955972 )
2019
373
Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide-resistance in castration-resistance prostate cancer. ( 31085587 )
2019
374
Presence of sarcopenic obesity and evaluation of the associated muscle quality in Japanese older men with prostate cancer undergoing androgen deprivation therapy. ( 30956136 )
2019
375
Prostate cancer metastasis and soy isoflavones: a dogfight over a bone. ( 30956643 )
2019
376
Very-high-risk (VHR) localized prostate cancer: an indication for multimodal therapy. ( 30956769 )
2019
377
Is Primary Androgen Deprivation Therapy a Suitable Option for Asian Patients With Prostate Cancer Compared With Radical Prostatectomy? ( 31085754 )
2019
378
Multimodal treatment for high risk locally advanced prostate cancer following radical prostatectomy and extended lymphadenectomy: results of a prospective cohort study with high-dose intensity-modulated radiation therapy, concurrent docetaxel and long-term androgen deprivation therapy. ( 30957475 )
2019
379
Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer. ( 31085758 )
2019
380
Primary Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer in Asia: Unique or Not? ( 31085760 )
2019
381
Time to biochemical relapse after radical prostatectomy and efficacy of salvage radiotherapy in patients with prostate cancer. ( 31087170 )
2019
382
(68Ga)-PSMA-PET/CT for the detection of postoperative prostate cancer recurrence: Possible implications on treatment volumes for radiation therapy. ( 31088725 )
2019
383
The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition. ( 31089709 )
2019
384
Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): a Randomised Controlled Phase 3 Trial. ( 30958755 )
2019
385
An expanded variant list and assembly annotation identifies multiple novel coding and noncoding genes for prostate cancer risk using a normal prostate tissue eQTL data set. ( 30958860 )
2019
386
Identification of candidate diagnostic and prognostic biomarkers for human prostate cancer: RPL22L1 and RPS21. ( 31089825 )
2019
387
TMPRSS2-ERG fusions linked to prostate cancer racial health disparities: A focus on Africa. ( 31090091 )
2019
388
Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer. ( 31090157 )
2019
389
Neurotensin Receptor-1 Expression in Human Prostate Cancer: A Pilot Study on Primary Tumors and Lymph Node Metastases. ( 30959962 )
2019
390
Associations of telomere length in risk and recurrence of prostate cancer: A meta-analysis. ( 31090230 )
2019
391
The Role of Long Non-coding RNA Prostate Cancer-Associated Transcript 1 in Prostate Cancer. ( 31090454 )
2019
392
Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015. ( 30962042 )
2019
393
Trends in complementary and alternative medicine use among patients with prostate cancer. ( 31091175 )
2019
394
More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. ( 31091398 )
2019
395
MIIP inhibits the growth of prostate cancer via interaction with PP1α and negative modulation of AKT signaling. ( 31092266 )
2019
396
Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. ( 31092338 )
2019
397
The role of hormone therapy and chemotherapy in oligometastatic prostate cancer. ( 30962966 )
2019
398
Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review. ( 31092382 )
2019
399
Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer. ( 30963355 )
2019
400
Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. ( 31092441 )
2019
401
SIRT1 modulates the sensitivity of prostate cancer cells to VSV oncolysis. ( 31092575 )
2019
402
Comparative evaluation of the new GRPR-antagonist 111 In-SB9 and 111 In-AMBA in prostate cancer models - Implications of in vivo stability. ( 30963606 )
2019
403
CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. ( 31092909 )
2019
404
Downregulation of long noncoding RNA LINC00683 associated with unfavorable prognosis in prostate cancer based on TCGA. ( 30963639 )
2019
405
MicroRNA-183-5p: A New Potential Marker for Prostate Cancer. ( 31092995 )
2019
406
Evaluation of 24-core coaxial needle saturation biopsy of the prostate by the transperineal approach in detecting prostate cancer in patients without previous biopsy history: A single-center report. ( 30964115 )
2019
407
Are decision aids leading to shared prostate cancer screening decisions among African-American men?: iDecide. ( 31093861 )
2019
408
Diagnostic performance of 18F-fluciclovine PET/CT for regional lymph node metastases in patients with primary prostate cancer: a multicenter phase II clinical trial. ( 31095314 )
2019
409
Radiogenomics Consortium Genome-Wide Association Study Meta-analysis of Late Toxicity after Prostate Cancer Radiotherapy. ( 31095341 )
2019
410
Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies. ( 30914334 )
2019
411
Appraising risk in active surveillance of localized prostate cancer. ( 31095822 )
2019
412
Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer. ( 31097763 )
2019
413
The impact of plasma zinc status on the severity of prostate cancer disease. ( 31098423 )
2019
414
The role of multiparametric MRI in biopsy-naive prostate cancer. ( 30914803 )
2019
415
EMT Markers in Locally-Advanced Prostate Cancer: Predicting Recurrence? ( 30915272 )
2019
416
Bioconjugated Gold Nanoparticles Enhance siRNA Delivery in Prostate Cancer Cells. ( 31099011 )
2019
417
Retraction: Festuccia, C., Gravina, G. L., Angelucci, A., Millimaggi, D., Muzi, P., Vicentini, C. and Bologna, M. (2005), Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int. J. Cancer, 115: 630-640. https://doi.org/10.1002/ijc.20917. ( 31099426 )
2019
418
Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure? ( 31099652 )
2019
419
The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families. ( 31099688 )
2019
420
Association of muscle mass with survival after radical prostatectomy in patients with prostate cancer. ( 30916628 )
2019
421
Prostate Cancer: How Nurse Practitioners Can Aid in Disease Diagnosis and Management. ( 31099786 )
2019
422
Calcium Channel Blocker Use and the Risk for Prostate Cancer: A Population-Based Nested Case-Control Study. ( 30917404 )
2019
423
Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration Resistant Prostate Cancer. ( 30918020 )
2019
424
Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer. ( 30919165 )
2019
425
Observed racial disparity in the negative predictive value of multi-parametric MRI for the diagnosis for prostate cancer. ( 31049779 )
2019
426
Raloxifene decreases cell viability and migratory potential in prostate cancer cells (LNCaP) with GPR30/GPER1 involvement. ( 30919959 )
2019
427
Letter to the Editor: "Integrative Genomic Analysis of OCT1 Reveals Coordinated Regulation of Androgen Receptor in Advanced Prostate Cancer". ( 30920586 )
2019
428
Health-related quality of life in long-term survivors with localised prostate cancer by therapy-Results from a population-based study. ( 31050091 )
2019
429
KDM5C is transcriptionally regulated by BRD4 and promotes castration-resistance prostate cancer cell proliferation by repressing PTEN. ( 30921702 )
2019
430
Impact of MRI on prostate cancer staging and EAU risk classification. ( 31051166 )
2019
431
Preparation of Titanocene-Gold Compounds Based on Highly Active Gold-NHeterocyclic Carbene Anticancer Agents. Preliminary in vitro Studies in Renal and Prostate Cancer Cell lines. ( 30924298 )
2019
432
Research Evidence on High-Fat Diet-Induced Prostate Cancer Development and Progression. ( 31052319 )
2019
433
Anti-Cancer Activity of Novel Dihydrotestosterone-Derived Ring A-Condensed Pyrazoles on Androgen Non-Responsive Prostate Cancer Cell Lines. ( 31052484 )
2019
434
Communicative aspects of decision aids for localized prostate cancer treatment - A systematic review. ( 31053529 )
2019
435
Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms. ( 30924452 )
2019
436
Initial 3-month dynamics of dehydroepiandrosterone sulfate can predict responsiveness to primary androgen deprivation therapy in patients with metastatic prostate cancer. ( 30924454 )
2019
437
Use of Bone Marrow-Derived Mesenchymal Stem Cells in Prostate Cancer Could Increase the Risk of Cancer Progression. ( 30925021 )
2019
438
Re: Targeting FOXA1-Mediated Repression of TGF-β Signaling Suppresses Castration-Resistant Prostate Cancer Progression. ( 30925087 )
2019
439
Re: Risk of Prostate Cancer in Men Treated with 5α-Reductase Inhibitors-A Large Population-Based Prospective Study. ( 30925094 )
2019
440
Imaging metastatic castration-resistant prostate cancer patients with 89Zr-DFO-MSTP2109A anti-STEAP1 antibody. ( 31053681 )
2019
441
Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial. ( 30925126 )
2019
442
LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide. ( 30925273 )
2019
443
Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). ( 31053766 )
2019
444
Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future. ( 30925537 )
2019
445
The impact of the three degrees-of-freedom fiducial marker-based setup compared to soft tissue-based setup in hypofractionated intensity-modulated radiotherapy for prostate cancer. ( 31054217 )
2019
446
Expression and Localization of DDX3 in Prostate Cancer Progression and Metastasis. ( 30926334 )
2019
447
Gold interdigitated triple-microelectrodes for label-free prognosticative aptasensing of prostate cancer biomarker in serum. ( 31054519 )
2019
448
Improved detection and reduced biopsies: the effect of a multiparametric magnetic resonance imaging-based triage prostate cancer pathway in a public teaching hospital. ( 31055625 )
2019
449
Delta-like Protein 3 Is a Target in Neuroendocrine Prostate Cancer. ( 30926615 )
2019
450
A Self-Fulfilling Prophecy: Comparing 177Lu-PSMA Radioligand therapy in Taxane Naïve vs Post-Taxane metastasized Prostate Cancer Patients? ( 30926648 )
2019
451
Investigating the role of constrained CVT and CVT in HIPO inverse planning for HDR brachytherapy of prostate cancer. ( 31055834 )
2019
452
Mechanistic insights into Nav1.7-dependent regulation of rat prostate cancer cell invasiveness revealed by toxin probes and proteomic analysis. ( 30927332 )
2019
453
AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer. ( 31055861 )
2019
454
A review of cone-beam CT applications for adaptive radiotherapy of prostate cancer. ( 30928061 )
2019
455
Predicting biochemical recurrence and prostate cancer specific mortality after radical prostatectomy: comparison of six prediction models in a cohort of screen and clinically detected prostate cancer patients. ( 31055875 )
2019
456
Re: Active Surveillance of Prostate Cancer is a Viable Option in Men Younger than 60 Years. ( 31056227 )
2019
457
Increased PSMA Expression in Castration-Resistant Prostate Cancer Metastases 3 Months After Initiation of Enzalutamide Indicated by 18F-DCFPyL PET/CT. ( 31058686 )
2019
458
Activation of PSGR with β-ionone suppresses prostate cancer progression by blocking androgen receptor nuclear translocation. ( 30928381 )
2019
459
Review of 18F-Fluciclovine PET for Detection of Recurrent Prostate Cancer. ( 31059396 )
2019
460
Metastatic prostate cancer cells are highly sensitive to 3-bromopyruvic acid. ( 30928407 )
2019
461
Glycidamide Promotes the Growth and Migratory Ability of Prostate Cancer Cells by Changing the Protein Expression of Cell Cycle Regulators and Epithelial-to-Mesenchymal Transition (EMT)-Associated Proteins with Prognostic Relevance. ( 31060254 )
2019
462
A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer. ( 31060542 )
2019
463
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer. ( 31060606 )
2019
464
Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. ( 31060822 )
2019
465
The clinical utility of prostate cancer heterogeneity using texture analysis of multiparametric MRI. ( 30929224 )
2019
466
Proteomic profiling of human prostate cancer-associated fibroblasts (CAF) reveals LOXL2-dependent regulation of the tumor microenvironment. ( 31061140 )
2019
467
Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection. ( 30929322 )
2019
468
Signature maps for automatic identification of prostate cancer from colorimetric analysis of H&E- and IHC-stained histopathological specimens. ( 31061447 )
2019
469
Diagnosis of prostate cancer. ( 31061798 )
2019
470
The role of radiotherapy in localised and locally advanced prostate cancer. ( 31061801 )
2019
471
Dose escalation of external beam radiotherapy for high-risk prostate cancer-Impact of multiple high-risk factor. ( 31061806 )
2019
472
Putting Prostate Cancer Metabolism into the Right Context. ( 30929844 )
2019
473
Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series. ( 31062066 )
2019
474
Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: single-center evaluation of 6-month treatment safety and functional outcomes of intensified treatment parameters. ( 31062122 )
2019
475
Cycling for renewal: Cell cycle machinery maintains prostate cancer stem-like cells. ( 30930046 )
2019
476
Targeting the signalling pathways regulated by deubiquitinases for prostate cancer therapeutics. ( 31062387 )
2019
477
Enhanced targeting of prostate cancer-initiating cells by salinomycin-encapsulated lipid-PLGA nanoparticles linked with CD44 antibodies. ( 30930999 )
2019
478
MRI-Based Radiomics Signature for the Preoperative Prediction of Extracapsular Extension of Prostate Cancer. ( 31062459 )
2019
479
18F-Prostate-Specific Membrane Antigen 1007 and 18F-FCH PET/CT in Local Recurrence of Prostate Cancer. ( 30932984 )
2019
480
Using prognosis to guide inclusion criteria, define standardized end-points and stratify follow up in active surveillance for prostate cancer. ( 31063245 )
2019
481
Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or…. ( 30933324 )
2019
482
The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer. ( 30933552 )
2019
483
Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo. ( 30933831 )
2019
484
Upregulation of Scavenger receptor B1 is required for steroidogenic and non-steroidogenic cholesterol metabolism in prostate cancer. ( 31064850 )
2019
485
The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis. ( 30934773 )
2019
486
Hormetic Dose Response of NaAsO2 on Cell Proliferation of Prostate Cells in Vitro: Implications for Prostate Cancer Initiation and Therapy. ( 31065237 )
2019
487
Exploring the impact of providing men with information about potential prostate cancer treatment options prior to receiving biopsy results. ( 31065839 )
2019
488
High Concentrations of Boric Acid Trigger Concentration-Dependent Oxidative Stress, Apoptotic Pathways and Morphological Alterations in DU-145 Human Prostate Cancer Cell Line. ( 31066018 )
2019
489
How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer? ( 31066510 )
2019
490
Lymph Nodes Invasion of Marcille's Fossa Associates with High Metastatic Load in Prostate Cancer Patients Undergoing Extended Pelvic Lymph Node Dissection: The Role of "Marcillectomy". ( 31067558 )
2019
491
Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. ( 30935383 )
2019
492
Reprogramming of isocitrate dehydrogenases expression and activity by the androgen receptor in prostate cancer. ( 31068457 )
2019
493
Epidemiology of Prostate Cancer. ( 31068988 )
2019
494
Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer. ( 31069149 )
2019
495
Multiparametric magnetic resonance imaging in prostate cancer detection. ( 31070133 )
2019
496
Key factors associated with social distress after prostate cancer: Results from the United Kingdom Life after Prostate Cancer diagnosis study. ( 31071525 )
2019
497
Does plasma thiol and disulphide be a new marker for prostate cancer in prostate-specific antigen level between 10 and 20 ng/ml? ( 31072170 )
2019
498
Aspirin Exposure and Mortality Risk among Prostate Cancer Patients: A Systematic Review and Meta-Analysis. ( 31073532 )
2019
499
Salvage radical prostatectomy for recurrent prostate cancer: morbidity and functional outcomes from a large multicenter series of open versus robotic approaches. ( 31075058 )
2019
500
Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience. ( 30937295 )
2019
501
Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. ( 31076357 )
2019
502
Correction to: A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL. ( 30937691 )
2019
503
Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset. ( 30885533 )
2019
504
Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer. ( 30885648 )
2019
505
Trastuzumab co-treatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26. ( 31077356 )
2019
506
Pathological Characteristics of Prostate Cancer in Men Aged < 50 Years Treated with Radical Prostatectomy: a Multi-Centre Study in Korea. ( 30886549 )
2019
507
Association among plasma 1,25(OH)2 D, ratio of 1,25(OH)2 D to 25(OH)D, and prostate cancer aggressiveness. ( 31077420 )
2019
508
An immunosensing device based on inhibition of mediator's faradaic process for early diagnosis of prostate cancer using bifunctional nanoplatform reinforced by carbon nanotube. ( 31078062 )
2019
509
Effectiveness of Platinum-Based Chemotherapy in Patients With Metastatic Prostate Cancer: Systematic Review and Meta-analysis. ( 31023519 )
2019
510
An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. ( 31023626 )
2019
511
Qualitative Evaluation of a Community-Based Physical Activity and Yoga Program for Men Living With Prostate Cancer: Survivor Perspectives. ( 31024755 )
2019
512
Geographical Variations in Prostate Cancer Outcomes: A Systematic Review of International Evidence. ( 31024842 )
2019
513
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. ( 30887825 )
2019
514
Diagnostic performance of 68Ga-PSMA PET/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections. ( 31025048 )
2019
515
TRPM2 mediates distruption of autophagy machinery and correlates with the grade level in prostate cancer. ( 30888515 )
2019
516
Novel Gastrin-Releasing Peptide Receptor Targeted Near-Infrared Fluorescence Dye for Image-Guided Surgery of Prostate Cancer. ( 31025163 )
2019
517
Prostate Imaging Reporting and Data System Version 2 for MRI of Prostate Cancer: Can We Do Better? ( 30888865 )
2019
518
Palliative transurethral resection of the prostate in patients with metastatic prostate cancer: a prospective study of 188 patients. ( 31025578 )
2019
519
What Are the Experiences of Men Affected by Prostate Cancer Participating in an Ecological Momentary Assessment Study? ( 30888981 )
2019
520
Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study. ( 31026211 )
2019
521
Detection of Local Relapse of Prostate Cancer With 18F-PSMA-1007. ( 30889005 )
2019
522
Serine and Methionine Metabolism: Vulnerabilities in Lethal Prostate Cancer. ( 30889375 )
2019
523
Rho-Associated Protein Kinase (ROCK) Promotes Proliferation and Migration of PC-3 and DU145 Prostate Cancer Cells by Targeting LIM Kinase 1 (LIMK1) and Matrix Metalloproteinase-2 (MMP-2). ( 31026254 )
2019
524
Structural Insights into BET Client Recognition of Endometrial and Prostate Cancer-Associated SPOP Mutants. ( 31026449 )
2019
525
Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer. ( 31027362 )
2019
526
Radiation dosimetry and biodistribution of 18F-PSMA-11 for PET imaging of prostate cancer. ( 31028165 )
2019
527
Is digital rectal examination still useful in prostate cancer diagnosis? YES! ( 30890104 )
2019
528
Is digital rectal examination still useful in prostate cancer diagnosis? NO! ( 30890105 )
2019
529
Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. ( 30890759 )
2019
530
Prostate cancer recurrence presenting as an isolated small bowel tumour. ( 30891174 )
2019
531
Endocrine Disrupting-Chemicals and Biochemical Recurrence of Prostate Cancer after Prostatectomy: A cohort study in Guadeloupe (French West Indies). ( 30892691 )
2019
532
The evolving role of diet in prostate cancer risk and progression. ( 30893147 )
2019
533
Anti-PD-1-CTLA4 Combo Hits Prostate Cancer. ( 30894362 )
2019
534
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. ( 30894499 )
2019
535
Repurposed Drugs for Prostate Cancer. ( 30896534 )
2019
536
Metformin use and prostate cancer risk: A meta-analysis of cohort studies. ( 30896668 )
2019
537
Nutlin3a-Loaded Nanoparticles Show Enhanced Apoptotic Activity on Prostate Cancer Cells. ( 31028604 )
2019
538
Urologist practice structure and spending for prostate cancer care. ( 31029672 )
2019
539
Targeting hormone refractory prostate cancer by in vivo selected DNA libraries in an orthotopic xenograft mouse model. ( 30899039 )
2019
540
Combination of the natural product capsaicin and docetaxel synergistically kills human prostate cancer cells through the metabolic regulator AMP-activated kinase. ( 30899201 )
2019
541
Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance. ( 31031042 )
2019
542
Leukemia inhibitory factor promotes castration-resistant prostate cancer and neuroendocrine differentiation by activated ZBTB46. ( 30962287 )
2019
543
A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens. ( 30899904 )
2019
544
Lymphatic micrometastases predict biochemical recurrence in patients undergoing radical prostatectomy and pelvic lymph node dissection for prostate cancer. ( 30900232 )
2019
545
Secreted protein acidic and rich in cysteine (SPARC) induces epithelial-mesenchymal transition, enhancing migration and invasion, and is associated with high Gleason score in prostate cancer. ( 31031331 )
2019
546
The Identification of Potential Biomarkers and Biological Pathways in Prostate Cancer. ( 31031850 )
2019
547
Favorable long-term oncological and urinary outcomes of incidental prostate cancer following holmium laser enucleation of the prostate. ( 31031975 )
2019
548
Integrating systemic module inference with attract method excavates attractor modules for cyclophosphamide contributing to prostate cancer. ( 30900638 )
2019
549
Screening for prostate cancer starting at age 50-54 years. ( 30900644 )
2019
550
Weakly supervised natural language processing for assessing patient-centered outcome following prostate cancer treatment. ( 31032481 )
2019
551
The percentage of high grade disease in prostate biopsies significantly improves on grade groups in prediction of prostate cancer death. ( 31032963 )
2019
552
Analysis of the high-dose-range radioresistance of prostate cancer cells, including cancer stem cells, based on a stochastic model. ( 31034058 )
2019
553
Multidisciplinary Care in High-Risk Prostate Cancer Is the New Standard of Care. ( 30901303 )
2019
554
Evaluating the Potential Role of Salvage Vesiculectomy for Prostate Cancer Recurrence. ( 30902522 )
2019
555
Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. ( 31034601 )
2019
556
Placing prostate cancer disparities within a psychosocial context: challenges and opportunities for future research. ( 30903484 )
2019
557
IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy. ( 30903647 )
2019
558
Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of β-catenin in cancer stem-like cells. ( 30904606 )
2019
559
Raddeanin A down-regulates androgen receptor and its splice variants in prostate cancer. ( 30905075 )
2019
560
Second cancers in radically treated Norwegian prostate cancer patients. ( 30905229 )
2019
561
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. ( 31036442 )
2019
562
Serum PSA levels in patients with prostate cancer and other 33 different types of diseases. ( 30905464 )
2019
563
Re: A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. ( 30905514 )
2019
564
Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. ( 31036925 )
2019
565
Incidental finding of non-Hodgkin's lymphoma in a patient affected by castration-sensitive prostate cancer: A case report. ( 30882658 )
2019
566
Impact of α-adrenoceptor antagonists on prostate cancer development, progression and prevention. ( 30906804 )
2019
567
Radiation-related Lymphopenia after Pelvic Nodal Irradiation for Prostate Cancer. ( 31011677 )
2019
568
Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer. ( 31037562 )
2019
569
High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes. ( 30908894 )
2019
570
Effect of Vitamin D Supplementation in Prostate Cancer: A Systematic Review of Randomized Control Trials. ( 31038028 )
2019
571
RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. ( 30910347 )
2019
572
New prognostic model for prostate cancer. ( 30910515 )
2019
573
Preference-based intervention in prostate cancer. ( 30910516 )
2019
574
A continuous fall of PSA use for prostate cancer screening among Brazilian doctors since 2001. Good or bad notice? ( 31038862 )
2019
575
Utility of Restriction Spectrum Imaging Among Men Undergoing First-Time Biopsy for Suspected Prostate Cancer. ( 31039011 )
2019
576
Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer. ( 31039025 )
2019
577
Re: Comparison of Gleason upgrading rates in transrectal ultrasound systematic random biopsies versus US-MRI fusion biopsies for prostate cancer. ( 30912891 )
2019
578
Emerging therapeutic targets for patients with advanced prostate cancer. ( 30913454 )
2019
579
Management algorithms for metastatic prostate cancer. ( 31039111 )
2019
580
Incidence of prostate cancer among patients with prostate-related urinary symptoms: A single institution series in 10 years. ( 31040596 )
2019
581
Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today? ( 30861092 )
2019
582
Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today? ( 30861093 )
2019
583
Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer. ( 31040745 )
2019
584
Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection. ( 31042322 )
2019
585
Causes of death in men with prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata). ( 30861444 )
2019
586
Dual-time-point 64 Cu-PSMA-617-PET/CT in patients suffering from prostate cancer. ( 31042811 )
2019
587
Is prostate volume better than PSA density and free/total PSA ratio in predicting prostate cancer in patients with PSA 2.5-10 ng/mL and 10.1-30 ng/mL? ( 30862227 )
2019
588
A chemoenzymatically synthesized cholesterol-g-poly(amine-co-ester)-mediated p53 gene delivery for achieving antitumor efficacy in prostate cancer. ( 30863051 )
2019
589
Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer. ( 31043681 )
2019
590
Circular RNA circHIPK3 promotes cell proliferation and invasion of prostate cancer by sponging miR-193a-3p and regulating MCL1 expression. ( 30863152 )
2019
591
Polo-like kinase 3 is associated with poor prognosis and regulates proliferation and metastasis in prostate cancer. ( 30863161 )
2019
592
The X-linked tumor suppressor TSPX downregulates cancer-drivers/oncogenes in prostate cancer in a C-terminal acidic domain dependent manner. ( 30863497 )
2019
593
Effect of docetaxel on the regulation of proliferation and apoptosis of human prostate cancer cells. ( 30864701 )
2019
594
Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment. ( 31044095 )
2019
595
Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity. ( 30864833 )
2019
596
Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. ( 30865311 )
2019
597
Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens. ( 31045262 )
2019
598
Radical Surgery or Watchful Waiting in Prostate Cancer. ( 30865808 )
2019
599
Radical Surgery or Watchful Waiting in Prostate Cancer. Reply. ( 30865809 )
2019
600
Re: Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. ( 30865852 )
2019
601
Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care-Part 1: The Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer. ( 30866035 )
2019
602
The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease. ( 31045265 )
2019
603
Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer. ( 31045266 )
2019
604
Potential effect of anti-inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsy. ( 31045267 )
2019
605
A novel approach for assessment of prostate cancer aggressiveness using survivin-driven tumour-activatable minicircles. ( 30867586 )
2019
606
Prostate Cancer Surveillance After Radiation Therapy in a National Delivery System. ( 30867631 )
2019
607
Skeletal-Related Events in Patients With Multiple Myeloma and Prostate Cancer Who Receive Standard vs Extended-Interval Bisphosphonate Dosing. ( 30867632 )
2019
608
Prevalence, Predictors, and Implications for Appropriate Use of Active Surveillance Management Among Black Men Diagnosed With Low-risk Prostate Cancer. ( 31045876 )
2019
609
Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy. ( 31047783 )
2019
610
National trends in the utilization of androgen deprivation therapy for very low risk prostate cancer. ( 31047912 )
2019
611
miR-493 Promotes Prostate Cancer Cells Proliferation by Targeting PHLPP2 and Activating Akt Signaling Pathway. ( 30868840 )
2019
612
Decreased miR-218-5p Levels as a Serum Biomarker in Bone Metastasis of Prostate Cancer. ( 30870834 )
2019
613
A novel fully human antibody targeting extracellular domain of PSMA inhibits tumor growth in prostate cancer. ( 31048359 )
2019
614
Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells. ( 30871130 )
2019
615
Diagnostic Value of Platelet-To-Lymphocyte Ratio in Prostate Cancer. ( 31049087 )
2019
616
Eyeing Enzalutamide for Hormone-Sensitive Prostate Cancer. ( 30872263 )
2019
617
Oligometastatic Prostate Cancer. ( 30995848 )
2019
618
The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer. ( 30872920 )
2019
619
A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2). ( 30996073 )
2019
620
Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer. ( 30996285 )
2019
621
CTCF regulates the FoxO signaling pathway to affect the progression of prostate cancer. ( 30873749 )
2019
622
Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA. ( 30996714 )
2019
623
Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice. ( 30997868 )
2019
624
PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. ( 30999388 )
2019
625
Simplified Methods for Quantification of 18F-DCFPyL Uptake in Patients with Prostate Cancer. ( 31000583 )
2019
626
Phase 2 Multicenter Study of Gantry-Based Stereotactic Radiotherapy Boost for Intermediate and High Risk Prostate Cancer (PROMETHEUS). ( 31001481 )
2019
627
18F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies. ( 30877561 )
2019
628
Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer. ( 31002252 )
2019
629
Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer. ( 31002323 )
2019
630
Deubiquitinase USP9X regulates the invasion of prostate cancer cells by regulating the ERK pathway and mitochondrial dynamics. ( 31002345 )
2019
631
Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification. ( 31002732 )
2019
632
Different therapeutic regimens in the treatment of metastatic prostate cancer by performing a Bayesian network meta-analysis. ( 31002882 )
2019
633
Re: Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger than 60 Years. ( 30879792 )
2019
634
Stereotactic Body Radiotherapy Boost for Intermediate Risk Prostate Cancer: A Phase 1 Dose Escalation Study. ( 31002941 )
2019
635
Non-NAD-like PARP-1 inhibitors in prostate cancer treatment. ( 30880062 )
2019
636
Who Can Avoid Systematic Biopsy Without Missing Clinically Significant Prostate Cancer in Men Who Undergo Magnetic Resonance Imaging-Targeted Biopsy? ( 31003892 )
2019
637
Race-associated expression of MHC class I polypeptide-related sequence A (MICA) in prostate cancer. ( 31004600 )
2019
638
Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center. ( 31005183 )
2019
639
The accumulation of metabolic syndrome components is associated with higher risk of positive surgical margin among patients with localized prostate cancer after radical prostatectomy. ( 30881016 )
2019
640
Patient-Reported Sexual Survivorship Following High-Dose Image-Guided Proton Therapy for Prostate Cancer. ( 31005217 )
2019
641
Awareness of prostate cancer diagnosis and management among Turkish males: a cross sectional study from Çorum. ( 31007118 )
2019
642
Radical Prostatectomy or Radiotherapy for High and Very High Risk Prostate Cancer: A Multidisciplinary Clinic Experience of Patients Eligible for Either Treatment. ( 31009137 )
2019
643
Financial Margins for Prostate Cancer Surgery: Quantifying the Impact of Modifiable Cost Inputs in an Episode-based Reimbursement Model. ( 31009291 )
2019
644
Metabolomics-Based Biosignatures of Prostate Cancer in Patients Following Radiotherapy. ( 31009330 )
2019
645
MSC.sTRAIL Has Better Efficacy than MSC.FL-TRAIL and in Combination with AKTi Blocks Pro-Metastatic Cytokine Production in Prostate Cancer Cells. ( 31010082 )
2019
646
Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro. ( 31010254 )
2019
647
Quantitative proteomic analysis of prostate tissue specimens identifies deregulated protein complexes in primary prostate cancer. ( 31011308 )
2019
648
Serum Testosterone 60 Months after Passive-Scatter Proton Therapy for Localized Prostate Cancer. ( 30836776 )
2019
649
Oxidative DNA Damage-Mediated Genomic Heterogeneity Is Regulated by NKX3.1 in Prostate Cancer. ( 30836777 )
2019
650
Correction: Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease. ( 30837682 )
2019
651
Global Genetics Research in Prostate Cancer: A Text Mining and Computational Network Theory Approach. ( 30838019 )
2019
652
Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases. ( 31011676 )
2019
653
Characterization of human infiltrating and circulating gamma-delta T cells in prostate cancer. ( 30838341 )
2019
654
Regional Differences in the Treatment of Localized Prostate Cancer: An Analysis of Surgery and Radiation Utilization in the United States. ( 31011678 )
2019
655
Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer. ( 31012125 )
2019
656
Perioperative venous thromboembolism prophylaxis in prostate cancer surgery. ( 30840115 )
2019
657
Outcomes of universal germline testing for men with prostate cancer in an Australian tertiary center. ( 31012270 )
2019
658
Treatment-Related Sexual Side Effects From the Perspective of Partners of Men With Prostate Cancer. ( 31012384 )
2019
659
Hormone Therapy and Castration Resistance of Prostate Cancer. ( 31012829 )
2019
660
Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer. ( 31012989 )
2019
661
PEG10 is associated with treatment-induced neuroendocrine prostate cancer. ( 31013476 )
2019
662
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. ( 30843003 )
2019
663
STAT3 Post-Translational Modifications Drive Cellular Signaling Pathways in Prostate Cancer Cells. ( 31013746 )
2019
664
Chemical manipulations on the 1,4-dioxane ring of 5-HT1A receptor agonists lead to antagonists endowed with antitumor activity in prostate cancer cells. ( 30844609 )
2019
665
A Population-Based Study of Secondary Prostate Cancer Risk after Radiotherapy in Male Patients with Rectal Cancer: A Retrospective Cohort Study. ( 31013982 )
2019
666
Prostate cancer awareness, case-finding, and early diagnosis: Interviews with undiagnosed men in Australia. ( 30845152 )
2019
667
Follow-up care after treatment for prostate cancer: evaluation of a supported self-management and remote surveillance programme. ( 31014282 )
2019
668
Percutaneous MR-guided whole-gland prostate cancer cryoablation: safety considerations and oncologic results in 30 consecutive patients. ( 30845821 )
2019
669
Metastases-free survival rate in non-metastatic castration-resistant prostate cancer: Now living on its own! ( 30846288 )
2019
670
Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone. ( 30846330 )
2019
671
Impact of bilateral biopsy-detected prostate cancer on an active surveillance population. ( 31014300 )
2019
672
Comparison of Orthogonal NLP Methods for Clinical Phenotyping and Assessment of Bone Scan Utilization among Prostate Cancer Patients. ( 31014980 )
2019
673
Uncommon presentation of medication-related osteonecrosis of the mandible in a patient with metastatic prostate cancer. ( 30814104 )
2019
674
Absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancer. ( 31015164 )
2019
675
Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. ( 30850323 )
2019
676
Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. ( 31015166 )
2019
677
Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): Results from a prospective clinical trial. ( 31015175 )
2019
678
Prostate Cancer Gene Regulatory Network Inferred from RNA-Seq Data. ( 31015790 )
2019
679
Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome. ( 31016435 )
2019
680
The Sexual Functioning of Gay and Bisexual Men Following Prostate Cancer Treatment: Results from the Restore Study. ( 31016492 )
2019
681
Comprehensive Evaluation of Focal Therapy Complications in Prostate Cancer: A Standardised Methodology. ( 31017001 )
2019
682
Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study. ( 31017087 )
2019
683
Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway. ( 30851421 )
2019
684
Corrigendum to "Parveen Kumar, Vinay Narwal, Ranjana Jaiwal, C.S. Pundir, Construction and application of amperometric sarcosine biosensor based on SOxNPs/AuE for determination of prostate cancer" [Biosens. Bioelectron. 122 (2018) 144-146]. ( 30852069 )
2019
685
Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. ( 31017091 )
2019
686
ETS-related gene (ERG) expression as a predictor of oncological outcomes in patients with high-grade prostate cancer treated with primary androgen deprivation therapy: a cohort study. ( 30852544 )
2019
687
Magnetic resonance imaging features of pubic symphysis urinary fistula with pubic bone osteomyelitis in the treated prostate cancer patient. ( 30460532 )
2019
688
Application of Urinary Volatile Organic Compounds (VOCs) for the Diagnosis of Prostate Cancer. ( 30853355 )
2019
689
Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. ( 31017093 )
2019
690
Effect of PTEN loss on metabolic reprogramming in prostate cancer cells. ( 30854061 )
2019
691
Green tea-induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymes. ( 30854739 )
2019
692
Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review. ( 31017094 )
2019
693
Biomarkers in prostate cancer management. Is there something new? ( 30855011 )
2019
694
New markers in prostate cancer: Inmunohistochemical. ( 30855013 )
2019
695
Magnetic resonance imaging and prostate cancer: Perspectives from the UK, Europe and USA. ( 30855014 )
2019
696
Preclinical development of a WT1 oral cancer vaccine using a bacterial vector to treat castration-resistant prostate cancer. ( 30824610 )
2019
697
TREATMENT. Active surveillance in intermediate risk prostate cancer. ( 30855017 )
2019
698
Current concepts in oligometastatic prostate cancer: Is there a role for radical prostatectomy? ( 30855019 )
2019
699
High-risk prostate cancer. Optimal treatment. New evidences. ( 30855022 )
2019
700
Society of Behavior Medicine (SBM) Urges Congress to Ensure Affordable Care Act Coverage of Prostate Cancer Screening Support Services for High-Risk Men. ( 30855080 )
2019
701
Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. ( 31017095 )
2019
702
Effect of forced diuresis during 18F-DCFPyL PET/CT in patients with prostate cancer: activity in ureters, kidneys and bladder and occurrence of halo artefacts around kidneys and bladder. ( 30855543 )
2019
703
Testosterone therapy may reduce prostate cancer risk due to testosterone deficiency at a young age via stabilizing serum testosterone levels. ( 30857458 )
2019
704
Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis. ( 30964731 )
2019
705
Reply by authors: Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. ( 30857989 )
2019
706
Individual Comparison of Cholesterol Metabolism in Normal and Tumour Areas in Radical Prostatectomy Specimens from Patients with Prostate Cancer: Results of the CHOMECAP Study. ( 31017097 )
2019
707
ADP-Ribose and oxidative stress activate TRPM8 channel in prostate cancer and kidney cells. ( 30858386 )
2019
708
Ultrasensitive and reversible nanoplatform of urinary exosomes for prostate cancer diagnosis. ( 31017389 )
2019
709
Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer. ( 30858546 )
2019
710
Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac. ( 30859088 )
2019
711
Kinase PIM1 promotes prostate cancer cell growth via c-Myc-RPS7-driven ribosomal stress. ( 30859224 )
2019
712
Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. ( 30859273 )
2019
713
Prostate cancer dose-response, fractionation sensitivity and repopulation parameters evaluation from 25 international radiotherapy outcome data sets. ( 31017457 )
2019
714
YAP1 Is Involved in Tumorigenic Properties of Prostate Cancer Cells. ( 30859486 )
2019
715
Replication Study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. ( 30860027 )
2019
716
Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy. ( 30860083 )
2019
717
Are we ready to use hypofractionated instead of conventional radiotherapy for prostate cancer? Not yet. ( 30860337 )
2019
718
Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort. ( 30802002 )
2019
719
18PCholine transporter-like protein 1 (CTL1/SLC44A1) is a therapeutic target molecule for prostate cancer therapy. ( 30810170 )
2019
720
17PmicroRNA-16-5p enhances radiosensitivity through modulating cyclin D1/E1-pRb-E2F1 pathway in prostate cancer cells. ( 30810200 )
2019
721
9PSafety profile and therapeutic efficacy of one cycle of [177Lu]prostate-specific membrane antigen (PSMA) in end stage metastatic castration-resistant prostate cancer patients with low performance status. ( 30810201 )
2019
722
A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling. ( 31017696 )
2019
723
Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer. ( 30810466 )
2019
724
Twitter Response to the 2018 United States Preventive Services Task Force Guidelines on Prostate Cancer Screening. ( 30811805 )
2019
725
Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling. ( 31018021 )
2019
726
Inhibition of Tumor Growth by Dietary Indole-3-Carbinol in a Prostate Cancer Xenograft Model May Be Associated with Disrupted Gut Microbial Interactions. ( 30813350 )
2019
727
Heme Oxygenase 1 Impairs Glucocorticoid Receptor Activity in Prostate Cancer. ( 30813528 )
2019
728
Prediction of extraprostatic extension by MRI tumor contact length: difference between anterior and posterior prostate cancer. ( 30814680 )
2019
729
Differential tissue expression of extracellular vesicle-derived proteins in prostate cancer. ( 31018022 )
2019
730
Paraneoplastic Syndrome Secondary to Treatment Emergent Neuroendocrine Tumor in Metastatic Castration-resistant Prostate Cancer: A Unique Case. ( 30279116 )
2019
731
Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study. ( 30815799 )
2019
732
[Corrigendum] IL‑8 promotes proliferation and inhibition of apoptosis via STAT3/AKT/NF‑κB pathway in prostate cancer. ( 30816455 )
2019
733
Feasibility and Initial Results: Fluciclovine PET/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer. ( 30817240 )
2019
734
Down-Regulation of Nfatc1 Suppresses Proliferation, Migration, Invasion, and Warburg Effect in Prostate Cancer Cells. ( 30817743 )
2019
735
Graphene Oxide⁻Platinum Nanoparticle Nanocomposites: A Suitable Biocompatible Therapeutic Agent for Prostate Cancer. ( 31018506 )
2019
736
Misinformation on the Internet regarding Ablative Therapies for Prostate Cancer. ( 30817959 )
2019
737
The Hippo Pathway in Prostate Cancer. ( 31018586 )
2019
738
Stochastic frontier analysis as knowledge-based model to improve sparing of organs-at-risk for VMAT-treated prostate cancer. ( 30818294 )
2019
739
MicroRNA-3162-5p-Mediated Crosstalk Between Kallikrein Family Members Including Prostate-Specific Antigen in Prostate Cancer. ( 31018918 )
2019
740
Clinical impact of lower limb imaging in 68Ga-PSMA PET-CT for patients with prostate cancer. ( 31019043 )
2019
741
Incorporating Routine Magnetic Resonance Imaging-based Planning for the Delivery of High-dose-rate Brachytherapy for Prostate Cancer: An Evaluation of Clinical Feasibility and Dosimetric Outcomes. ( 31019863 )
2019
742
Active surveillance outcomes in prostate cancer patients: the use of transperineal template-guided mapping biopsy for patient selection. ( 31020423 )
2019
743
Focal Laser Ablation of Prostate Cancer: Results in 120 Patients with Low- to Intermediate-Risk Disease. ( 30819483 )
2019
744
Re: Prostate Cancer-specific Mortality Across Gleason Scores in Black vs Nonblack Men. ( 30819526 )
2019
745
Lu177-PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution. ( 31021525 )
2019
746
Super active surveillance for low-risk prostate cancer | Opinion: Yes. ( 31021584 )
2019
747
Reply to Xueliang Zhou and Xinwei Han's Letter to the Editor re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.011. ( 30967298 )
2019
748
Molecular Mechanisms and Bioavailability of Polyphenols in Prostate Cancer. ( 30823649 )
2019
749
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. ( 30824296 )
2019
750
Darolutamide Slows Metastasis in Prostate Cancer. ( 30824428 )
2019
751
Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNF alpha in Castration Resistant Prostate Cancer. ( 30824526 )
2019
752
Intratumoral sterol-27-hydroxylase (CYP27A1) expression in relation to cholesterol synthesis and vitamin D signaling and its association with lethal prostate cancer. ( 30867220 )
2019
753
Dietary choline and betaine intakes and risk of total and lethal prostate cancer in the Atherosclerosis Risk in Communities (ARIC) Study. ( 30825046 )
2019
754
Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care. ( 30967625 )
2019
755
Long-term survival of patients with prostate cancer in Martinique: Results of a population-based study. ( 30825842 )
2019
756
The Impact of Lifestyle-related Factors on Survival After a Prostate Cancer Diagnosis. ( 30826219 )
2019
757
Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up. ( 30826220 )
2019
758
Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study. ( 30968600 )
2019
759
Diagnostic Value of Circulating miR-324 for Prostate Cancer. ( 30969074 )
2019
760
Evaluation of Treatment Patterns and Costs in Patients with Prostate Cancer and Bone Metastases. ( 30827188 )
2019
761
Re: Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger than 60 Years. ( 30827693 )
2019
762
Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer. ( 30970027 )
2019
763
Programmed death ligand 1 expression in prostate cancer cells is associated with deep changes of the tumor inflammatory infiltrate composition. ( 30827759 )
2019
764
Long noncoding RNA GAS5 modulates α-Solanine-induced radiosensitivity by negatively regulating miR-18a in human prostate cancer cells. ( 30970507 )
2019
765
A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer. ( 30827923 )
2019
766
New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When. ( 30827924 )
2019
767
Class IIb HDAC Inhibition Enhances the Inhibitory Effect of Am80, a Synthetic Retinoid, in Prostate Cancer. ( 30828077 )
2019
768
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study). ( 30971225 )
2019
769
Differential effect of grape seed extract and its active constituent procyanidin B2 3,3″-di-O-gallate against prostate cancer stem cells. ( 30828884 )
2019
770
Differentially Expressed Genes and Molecular Pathways in an Autochthonous Mouse Prostate Cancer Model. ( 30972102 )
2019
771
Esophageal Stenosis by Prostate Cancer Metastasis. ( 30829678 )
2019
772
Predictive factors for short-term biochemical recurrence-free survival after robot-assisted laparoscopic radical prostatectomy in high-risk prostate cancer patients. ( 30972506 )
2019
773
Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre. ( 30972933 )
2019
774
Excellent Response to Lower Dose of 177Lu-PSMA-617 in a Metastatic Castration-Resistant Prostate Cancer Patient With a Transplanted Kidney. ( 30829871 )
2019
775
MP20-04 USABILITY AND TECHNICAL FEASIBILITY EVALUATION OF A TETHERED LAPAROSCOPIC GAMMA PROBE FOR RADIOGUIDED SURGERY IN PROSTATE CANCER: A PELVIC PHANTOM AND PORCINE MODEL STUDY. ( 30973819 )
2019
776
A Proposed Efficacious Treatment with Clioquinol (Zinc Ionophore) and Cabergoline (Prolactin Dopamine Agonist) for the Treatment of Terminal Androgen-independent Prostate Cancer. Why and How? ( 30828702 )
2019
777
Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis. ( 30973905 )
2019
778
Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion. ( 30975102 )
2019
779
Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer. ( 30975171 )
2019
780
Mycoplasma genitalium Infection and Chronic Inflammation in Human Prostate Cancer: Detection Using Prostatectomy and Needle Biopsy Specimens. ( 30832347 )
2019
781
L-securinine inhibits cell growth and metastasis of human androgen-independent prostate cancer DU145 cells via regulating mitochondrial and AGTR1/MEK/ERK/STAT3/PAX2 apoptotic pathways. ( 30975734 )
2019
782
Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments. ( 30976102 )
2019
783
Patient-Friendly Summary of the ACR Appropriateness Criteria: Post-treatment Follow-up of Prostate Cancer. ( 30832834 )
2019
784
Salvage treatment for radio-recurrent prostate cancer: a review of literature with focus on recent advancements in image-guided focal salvage therapies. ( 30977019 )
2019
785
Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. ( 30833140 )
2019
786
What Patients and Partners Want in Interventions That Support Sexual Recovery After Prostate Cancer Treatment: An Exploratory Convergent Mixed Methods Study. ( 30833226 )
2019
787
Germline Testing for Men With Prostate Cancer: Navigating an Expanding New World of Genetic Evaluation for Precision Therapy and Precision Management. ( 30978156 )
2019
788
Response to Olaparib in a PALB2 Germline Mutated Prostate Cancer and Genetic Events Associated with Resistance. ( 30833416 )
2019
789
Inhibition of mouse RM-1 prostate cancer and B16F10 melanoma by the fusion protein of HSP65 & STEAP1 186-193. ( 30841425 )
2019
790
French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation. ( 30287350 )
2019
791
Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( 31067347 )
2019
792
Vitamin K intake and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. ( 30624568 )
2019
793
Advanced prostate cancer discovered with cancerous peritonitis: Case report. ( 30510901 )
2019
794
Safe usage of bicalutamide and goserelin in a male patient with acute intermittent porphyria and prostate cancer. ( 30714461 )
2019
795
Safety of SBRT in post TURP prostate cancer patients: A propensity score matched pair analysis. ( 30978467 )
2019
796
Rectal volume variations and estimated rectal dose during 8 weeks of image-guided radical 3D conformal external beam radiotherapy for prostate cancer. ( 30834350 )
2019
797
Low-Dose-Rate and High-Dose-Rate Brachytherapy for Localized Prostate Cancer in ABO-Incompatible Renal Transplant Recipients. ( 30979463 )
2019
798
Editorial Comment to Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: regulation of NCAPH by antitumor miR-199a/b-3p. ( 30834615 )
2019
799
Novel Imaging in Detection of Metastatic Prostate Cancer. ( 30834999 )
2019
800
Radiomic Machine Learning: Is It Really a Useful Method for the Characterization of Prostate Cancer? ( 30835185 )
2019
801
ZFHX3 is indispensable for ERβ to inhibit cell proliferation via MYC downregulation in prostate cancer cells. ( 30979864 )
2019
802
Early Stage Biomarkers Screening of Prostate Cancer Based on Weighted Gene Coexpression Network Analysis. ( 30835547 )
2019
803
In honor of Dr. Donald S. Coffey - Prostate cancer biology and therapy. ( 30775243 )
2019
804
Current progress and questions in germline genetics of prostate cancer. ( 30775244 )
2019
805
Dietary inflammatory index (DII) and risk of prostate cancer in a case-control study among Black and White US Veteran men. ( 30980026 )
2019
806
Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer. ( 30775248 )
2019
807
Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome. ( 30980038 )
2019
808
Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics. ( 30775250 )
2019
809
Knockdown of lncRNA MNX1-AS1 suppresses cell proliferation, migration, and invasion in prostate cancer. ( 30980513 )
2019
810
An Evaluation of Follow-Up Activities of Participants From an Urban Prostate Cancer Screening Event. ( 30982387 )
2019
811
Growth inhibition of human breast and prostate cancer cells by cinnamic acid derivatives and their mechanism of action. ( 30982786 )
2019
812
Transcriptional changes in prostate of men on active surveillance after a 12-mo glucoraphanin-rich broccoli intervention-results from the Effect of Sulforaphane on prostate CAncer PrEvention (ESCAPE) randomized controlled trial. ( 30982861 )
2019
813
Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases. ( 30776136 )
2019
814
Blood and Dietary Magnesium Levels are not linked with lower Prostate Cancer Risk in Black or White Men. ( 30776477 )
2019
815
Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. ( 30777011 )
2019
816
The Tumor Immune Contexture of Prostate Cancer. ( 30984182 )
2019
817
First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands. ( 30985436 )
2019
818
Effective Technology-based Behaviour Change Interventions in Prostate Cancer Supportive Care: Are We There Yet? ( 30777371 )
2019
819
Targeted Biopsy Validation of Peripheral Zone Prostate Cancer Characterization With Magnetic Resonance Fingerprinting and Diffusion Mapping. ( 30985480 )
2019
820
Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments. ( 30986263 )
2019
821
The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis. ( 30778081 )
2019
822
Prostate cancer: a tale of two sides. ( 30778198 )
2019
823
Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis. ( 30986955 )
2019
824
MiR-492 exerts tumor-promoting function in prostate cancer through repressing SOCS2 expression. ( 30779065 )
2019
825
AICAR Induces Apoptosis and Inhibits Migration and Invasion in Prostate Cancer Cells Through an AMPK/mTOR-Dependent Pathway. ( 30987073 )
2019
826
Impact of access to novel therapies on the initial management of castrate-resistant prostate cancer: an Australian multicentre study. ( 30779277 )
2019
827
N-Terminal Domain Mediated Regulation of RORα1 Inhibits Invasive Growth in Prostate Cancer. ( 30987323 )
2019
828
Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice. ( 30779980 )
2019
829
Experiences of UK African-Caribbean prostate cancer survivors of discharge to primary care. ( 30987446 )
2019
830
Prostate care and prostate cancer from the perspectives of undiagnosed men: a systematic review of qualitative research. ( 30782686 )
2019
831
Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. ( 30987843 )
2019
832
Re: Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients with High-risk Prostate Cancer with Rising Prostate-specific Antigen Levels After Primary Local Therapy A Randomized Clinical Trial. ( 30987844 )
2019
833
Does exercise impact gut microbiota composition in men receiving androgen deprivation therapy for prostate cancer? A single-blinded, two-armed, randomised controlled trial. ( 30987986 )
2019
834
Sinomenine inhibits proliferation, migration, invasion and promotes apoptosis of prostate cancer cells by regulation of miR-23a. ( 30784907 )
2019
835
Stroke and thromboembolic events in men with prostate cancer treated with definitive radiation therapy with or without androgen deprivation therapy. ( 30988408 )
2019
836
Secreted frizzled-related protein 5 suppresses aggressive phenotype and reverses docetaxel resistance in prostate cancer. ( 30787036 )
2019
837
Eukaryotic translation initiation factor 5A2 is highly expressed in prostate cancer and predicts poor prognosis. ( 30988760 )
2019
838
Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer. ( 30787671 )
2019
839
Interleukin-8 promotes prostate cancer bone metastasis through upregulation of bone sialoprotein. ( 30988819 )
2019
840
Incidence of Prostate Cancer according to Metabolic Health Status: a Nationwide Cohort Study. ( 30787682 )
2019
841
Site-specific post-imprinting modification of molecularly imprinted polymer nanocavities with a modifiable functional monomer for prostate cancer biomarker recognition. ( 30988832 )
2019
842
Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI). ( 30788558 )
2019
843
The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer. ( 30788590 )
2019
844
Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy. ( 30989489 )
2019
845
Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805). ( 30789412 )
2019
846
Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer. ( 30990564 )
2019
847
Lifestyles, health habits, and prostate cancer. ( 30790052 )
2019
848
RNASEL 1623A>C variant is associated with the risk of prostate cancer in African descendants. ( 30790337 )
2019
849
Three-dimensional greyscale transrectal ultrasound-guidance and biopsy core preembedding for detection of prostate cancer: Dutch clinical cohort study. ( 30991993 )
2019
850
Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase. ( 30790678 )
2019
851
Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. ( 30992160 )
2019
852
Computer-Aided Discovery of Small Molecules Targeting the RNA Splicing Activity of hnRNP A1 in Castration-Resistant Prostate Cancer. ( 30791548 )
2019
853
Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer. ( 30992298 )
2019
854
Multimodality Hyperpolarized C-13 MRS/PET/Multiparametric MR Imaging for Detection and Image-Guided Biopsy of Prostate Cancer: First Experience in a Canine Prostate Cancer Model. ( 30793241 )
2019
855
Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: An evolution-based strategy. ( 30992299 )
2019
856
Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone. ( 30794306 )
2019
857
Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. ( 30794477 )
2019
858
A critical appraisal of biomarkers in prostate cancer. ( 30993424 )
2019
859
Effect of genetic variants in cell adhesion pathways on the biochemical recurrence in prostate cancer patients with radical prostatectomy. ( 30993852 )
2019
860
Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. ( 30995089 )
2019
861
Phloretin Inhibits the Human Prostate Cancer Cells Through the Generation of Reactive Oxygen Species. ( 30937835 )
2019
862
Artist, Rediscovered: Images and Ethics of Early Prostate Cancer Screening. ( 30938779 )
2019
863
Splicing Factors Have an Essential Role in Prostate Cancer Progression and Androgen Receptor Signaling. ( 30939845 )
2019
864
NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. ( 30940724 )
2019
865
The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. ( 30799188 )
2019
866
The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literature. ( 30941561 )
2019
867
The assessment of knowledge and attitudes of men in Serbia about prostate cancer and possibilities for its early detection and treatment in 2011: a cross-sectional study. ( 30941975 )
2019
868
Trends in Prostate Cancer Prevalence and Radical Prostatectomy Rate according to Age Structural Changes in South Korea between 2005 and 2015. ( 30799588 )
2019
869